bupropion has been researched along with Depression, Endogenous in 273 studies
Bupropion: A propiophenone-derived antidepressant and antismoking agent that inhibits the uptake of DOPAMINE.
bupropion : An aromatic ketone that is propiophenone carrying a tert-butylamino group at position 2 and a chloro substituent at position 3 on the phenyl ring.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Outpatients with chronic or recurrent major depression (MDD) were randomized to initial treatment with escitalopram+placebo (the MONO condition), bupropion-sustained release+escitalopram, or venlafaxine-extended release+mirtazapine (the COMB conditions) in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial." | 9.15 | Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. ( Bobo, WV; Chen, H; Cook, IA; Fava, M; Husain, MM; Kornstein, SG; Kurian, BT; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Shelton, RC; Stewart, JW; Trivedi, MH; Warden, D; Wisniewski, SR, 2011) |
| "This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms." | 9.14 | A bupropion smoking cessation clinical trial for cancer patients. ( Glass, M; Kuzla, N; Langer, C; Leone, F; Martinez, E; Miyamoto, C; Ridge, JA; Schnoll, RA; Tatum, KL; Weber, DM; Wileyto, EP, 2010) |
| " Our objective was to determine whether bupropion improves abstinence rates and abstinence-associated depressive symptoms when added to transdermal nicotine replacement therapy (NRT) and group cognitive behavioral therapy (CBT) in smokers with unipolar depressive disorder (UDD)." | 9.13 | A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. ( Alpert, JE; Culhane, MA; Evins, AE; Farabaugh, A; Fava, M; Liese, BS; Pava, J, 2008) |
| "Bupropion is an antidepressant shown to be efficacious for smoking cessation." | 9.11 | Effect of bupropion on depression symptoms in a smoking cessation clinical trial. ( Audrain-McGovern, J; Collins, BN; Epstein, LH; Hawk, L; Lerman, C; Niaura, R; Pinto, A; Wileyto, P, 2004) |
| "To evaluate the efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism, and changes in depressive symptoms during smoking abstinence." | 9.09 | Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. ( Croghan, IT; Glover, ED; Hayford, KE; Hurt, RD; Offord, KP; Patten, CA; Rummans, TA; Sachs, DP; Schroeder, DR, 1999) |
| "Subjects were participants in 2 randomized, double-blind, placebo-controlled studies investigating the efficacy of bupropion for smoking cessation." | 9.09 | Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports. ( Croghan, IT; Hays, JT; Hurt, RD; Patten, CA; Rummans, TA, 1999) |
| " We evaluated the addition of bupropion sustained release (SR) for smoking cessation among patients with a history of depressive disorders being maintained in a euthymic state with selective serotonin reuptake inhibitor (SSRI) antidepressants." | 9.09 | Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. ( Anderson, T; Atzert, R; Brar, JS; Chengappa, KN; Kambhampati, RK; Kang, JS; Key, P; Levine, J; Nigam, R; Perkins, K; Vemulapalli, HK, 2001) |
| "Patients diagnosed with major depressive disorder (MDD) and enrolled in an open-label safety surveillance study of a sustained release formulation of bupropion hydrochloride (100 to 300 mg/day) were evaluated with the Hamilton Rating Scale for Depression (HAM-D) immediately before and 6 to 12 weeks after the initiation of drug treatment." | 9.08 | Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder. ( Balogh, S; Burke, WJ; Fitzpatrick, DF; Hendricks, SE; Paige, SR, 1995) |
| "One randomised controlled trial met the inclusion criteria for the review, a comparison between topiramate and bupropion sustained release (SR) in the adjunctive treatment of depressed patients with bipolar disorder." | 8.83 | Topiramate for acute affective episodes in bipolar disorder. ( Geddes, J; Macritchie, K; Vasudev, K; Watson, S; Young, A, 2006) |
| "The aim of the current study was to analyse the augmentation of minocycline with bupropion in treating depression." | 7.91 | The effect of bupropion augmentation of minocycline in the treatment of depression. ( Addepalli, V; Bendale, M; DSouza, SR; Kale, PP, 2019) |
| "To the best of our knowledge, this is the third published case of bupropion-related eosinophilia." | 7.79 | Eosinophilia associated with bupropion. ( Aguirre, C; Etxegarai, E; García, M; Lertxundi, U; Ruiz, B, 2013) |
| "Bupropion, which is widely used in patients with depressive disorder, may cause allergic reactions." | 7.79 | Delayed onset urticaria in depressive patients with bupropion prescription: a nationwide population-based study. ( Chang, YS; Chen, MH; Chen, PM; Chen, TJ; Chiang, HL; Hu, LY; Hu, TM; Hu, YW; Liu, CJ; Lu, T; Shen, CC; Su, TP; Su, VY; Teng, CJ; Tsai, CF; Wang, WS; Yeh, CM, 2013) |
| "Ninety-three patients with type 2 diabetes and major depressive disorder (MDD) received bupropion hydrochloride in a two-phase, open-label treatment trial." | 7.74 | Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. ( Clouse, RE; Lustman, PJ; Nix, BD; Sayuk, GS; Williams, MM, 2007) |
| "To demonstrate that bupropion sustained release (SR) can reduce the symptoms of fatigue experienced by cancer patients." | 7.72 | Bupropion sustained release treatment reduces fatigue in cancer patients. ( Cullum, JL; Pelletier, G; Simpson, JS; Wojciechowski, AE, 2004) |
| "The authors report a case of bupropion-associated delirium characterized by disorganized thinking, memory impairment, fear, and agitation but not disorientation, delusions, hallucinations, or other perceptual distortions." | 7.68 | A case of bupropion-associated delirium. ( Dager, SR; Heritch, AJ, 1990) |
| "Bupropion treatment resulted in an improvement in depression on all outcome measures." | 6.67 | Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder. ( Apter, J; Ascher, J; Cunningham, L; Feighner, J; Ferguson, J; Ionescu-Pioggia, M; Johnston, JA; Merideth, C; Samara, B, 1994) |
| "Bupropion is a new antidepressant of the aminoketone class which is structurally unrelated to the tricyclics and which is relatively free of cardiac side effects in healthy depressed patients." | 6.66 | Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. ( Bigger, JT; Giardina, EG; Glassman, AH; Johnson, LL; Roose, SP; Walsh, BT, 1987) |
| "Bupropion is an antidepressant thought to work through effects on norepinephrine and dopamine." | 6.44 | Bupropion extended-release for depressive disorders. ( Jefferson, JW, 2008) |
| "The incidence of convulsions in patients receiving tricyclic antidepressants or bupropion was reviewed." | 6.36 | Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. ( Peck, AW; Stern, WC; Watkinson, C, 1983) |
| "Bupropion is a very popular medication prescribed to millions of patients globally for depression (Wellbutrin, GlaxoSmithKline, Research Triangle Park, NC) as well as an aid in smoking cessation (Zyban, GlaxoSmithKline, Research Triangle Park, NC)." | 5.36 | A case of bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation. ( Chon, SY; Riddel, C; Surovik, J, 2010) |
| " Six hundred and sixty-five outpatients with nonpsychotic, major depressive disorder were prospectively randomized to treatment with either a selective serotonin reuptake inhibitor (SSRI) monotherapy (escitalopram plus placebo) or one of two antidepressant medication combinations (bupropion-sustained release plus escitalopram, or venlafaxine-extended release plus mirtazapine)." | 5.16 | Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial. ( Davis, LL; Fava, M; Friedman, ES; Rush, AJ; Trivedi, MH; Wisniewski, SR; Zisook, S, 2012) |
| "Outpatients with chronic or recurrent major depression (MDD) were randomized to initial treatment with escitalopram+placebo (the MONO condition), bupropion-sustained release+escitalopram, or venlafaxine-extended release+mirtazapine (the COMB conditions) in the Combining Medications to Enhance Depression Outcomes (CO-MED) trial." | 5.15 | Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report. ( Bobo, WV; Chen, H; Cook, IA; Fava, M; Husain, MM; Kornstein, SG; Kurian, BT; Lesser, IM; Luther, JF; Morris, DW; Nierenberg, AA; Rush, AJ; Shelton, RC; Stewart, JW; Trivedi, MH; Warden, D; Wisniewski, SR, 2011) |
| "Relatively treatment-naive depressed outpatients (with DSM-IV diagnoses of major depressive disorder, dysthymic disorder, or depression not otherwise specified) were initially treated with a combination of escitalopram (ESC) plus bupropion (BUP), using rapid dose escalation to ESC 40 mg/day plus BUP 400 to 450 mg/day by study day 15 in an open-label, 8-week study." | 5.14 | Does dual antidepressant therapy as initial treatment hasten and increase remission from depression? ( Deliyannides, RA; McGrath, PJ; Quitkin, FM; Stewart, JW, 2009) |
| "This double-blind placebo-controlled trial randomized 246 cancer patients to 9 weeks of placebo or bupropion, stratifying by pre-treatment depression symptoms." | 5.14 | A bupropion smoking cessation clinical trial for cancer patients. ( Glass, M; Kuzla, N; Langer, C; Leone, F; Martinez, E; Miyamoto, C; Ridge, JA; Schnoll, RA; Tatum, KL; Weber, DM; Wileyto, EP, 2010) |
| " Our objective was to determine whether bupropion improves abstinence rates and abstinence-associated depressive symptoms when added to transdermal nicotine replacement therapy (NRT) and group cognitive behavioral therapy (CBT) in smokers with unipolar depressive disorder (UDD)." | 5.13 | A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders. ( Alpert, JE; Culhane, MA; Evins, AE; Farabaugh, A; Fava, M; Liese, BS; Pava, J, 2008) |
| "Bupropion is an antidepressant shown to be efficacious for smoking cessation." | 5.11 | Effect of bupropion on depression symptoms in a smoking cessation clinical trial. ( Audrain-McGovern, J; Collins, BN; Epstein, LH; Hawk, L; Lerman, C; Niaura, R; Pinto, A; Wileyto, P, 2004) |
| "Eleven boys and eight girls aged 11 to 17 years old were prescribed bupropion SR monotherapy for attention-deficit/hyperactivity disorder (n = 16) and/or depressive disorders (n = 16)." | 5.11 | Steady-state pharmacokinetics of bupropion SR in juvenile patients. ( Axelson, DA; Birmaher, B; Brent, DA; Daviss, WB; Gilchrist, R; Nuss, S; Perel, JM; Rudolph, GR, 2005) |
| "To evaluate the efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism, and changes in depressive symptoms during smoking abstinence." | 5.09 | Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism. ( Croghan, IT; Glover, ED; Hayford, KE; Hurt, RD; Offord, KP; Patten, CA; Rummans, TA; Sachs, DP; Schroeder, DR, 1999) |
| "Subjects were participants in 2 randomized, double-blind, placebo-controlled studies investigating the efficacy of bupropion for smoking cessation." | 5.09 | Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports. ( Croghan, IT; Hays, JT; Hurt, RD; Patten, CA; Rummans, TA, 1999) |
| "Elderly (> or = 60 years) outpatients with major depressive disorder (DSM-IV criteria) were evaluated in this 6-week multicenter, randomized, double-blind study comparing bupropion SR, 100-300 mg/day, and paroxetine, 10-40 mg/day." | 5.09 | Bupropion sustained release versus paroxetine for the treatment of depression in the elderly. ( Ascher, JA; Batey, SR; Donahue, RM; Houser, TL; Settle, EC; Weihs, KL, 2000) |
| "Bupropion SR may be effective and well-tolerated in adolescents with comorbid ADHD and depressive disorders." | 5.09 | Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression. ( Bentivoglio, P; Bostic, JQ; Brown, KM; Daviss, WB; Racusin, R; Wiley, L, 2001) |
| " We evaluated the addition of bupropion sustained release (SR) for smoking cessation among patients with a history of depressive disorders being maintained in a euthymic state with selective serotonin reuptake inhibitor (SSRI) antidepressants." | 5.09 | Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants. ( Anderson, T; Atzert, R; Brar, JS; Chengappa, KN; Kambhampati, RK; Kang, JS; Key, P; Levine, J; Nigam, R; Perkins, K; Vemulapalli, HK, 2001) |
| "Patients diagnosed with major depressive disorder (MDD) and enrolled in an open-label safety surveillance study of a sustained release formulation of bupropion hydrochloride (100 to 300 mg/day) were evaluated with the Hamilton Rating Scale for Depression (HAM-D) immediately before and 6 to 12 weeks after the initiation of drug treatment." | 5.08 | Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder. ( Balogh, S; Burke, WJ; Fitzpatrick, DF; Hendricks, SE; Paige, SR, 1995) |
| "Bupropion (BUP) may be less likely than other antidepressants to cause switches into mania and rapid cycling, suggesting utility in bipolar disorder." | 5.08 | Carbamazepine but not valproate induces bupropion metabolism. ( Callahan, AM; Chao, J; George, MS; Hinton, ML; Jenkins, JB; Ketter, TA; Marangell, LB; Pazzaglia, PJ; Post, RM; Schroeder, DH, 1995) |
| "Outpatients with moderate to severe major depressive disorder (DSM-IV) received bupropion SR (100-300 mg/day) or sertraline (50-200 mg/day) for 16 weeks." | 5.08 | Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients. ( Ascher, JA; Hughes, AR; Johnston, JA; Kavoussi, RJ; Segraves, RT, 1997) |
| "This prospective 105-site study was conducted to determine the rate of seizures and other serious adverse experiences associated with the therapeutic use of the sustained-release formulation of bupropion (bupropion SR)." | 5.08 | A prospective safety surveillance study for bupropion sustained-release in the treatment of depression. ( Ascher, JA; Batey, SR; Billow, AA; Dunner, DL; Johnston, JA; Zisook, S, 1998) |
| "This trial was conducted to determine the incidence of seizures associated with the use of bupropion." | 5.07 | A 102-center prospective study of seizure in association with bupropion. ( Ascher, JA; Davidson, J; Feighner, JP; Johnston, JA; Khayrallah, MA; Lineberry, CG; Stark, P, 1991) |
| "In a prospective, controlled, double-blind study, 37 patients with major depressive disorder were subclassified into primary depression (N = 25) and secondary (N = 12) depression and treated with either amitriptyline (primary depressives N = 13, secondary depressives N = 6) or bupropion (primary depressives N = 12, secondary depressives N = 6)." | 5.06 | Differential effect of amitriptyline and bupropion on primary and secondary depression: a pilot study. ( Mac, D; Othmer, E; Othmer, SC; Preskorn, SH, 1988) |
| "A double-blind multicenter evaluation compared the antidepressant efficacy of bupropion (Wellbutrin) to both placebo and amitriptyline (Elavil, Endep) in adult patients who met DSM-III criteria for major depressive disorder." | 5.05 | Antidepressant response and plasma concentrations of bupropion. ( Preskorn, SH, 1983) |
| "One randomised controlled trial met the inclusion criteria for the review, a comparison between topiramate and bupropion sustained release (SR) in the adjunctive treatment of depressed patients with bipolar disorder." | 4.83 | Topiramate for acute affective episodes in bipolar disorder. ( Geddes, J; Macritchie, K; Vasudev, K; Watson, S; Young, A, 2006) |
| "Alcoholism and nicotine dependence share many neurobiological underpinnings; the presence of one drug can cause a person to crave the other." | 4.83 | Treating smoking dependence in depressed alcoholics. ( Ait-Daoud, N; Breland, AB; Johnson, BA; Lynch, WJ; Marzani-Nissen, GR; Penberthy, JK, 2006) |
| " Bupropion is less likely than other antidepressants to cause weight gain and sexual dysfunction, the 2 side effects that are of greatest concern to patients and that have the greatest impact on long-term compliance." | 4.82 | Why isn't bupropion the most frequently prescribed antidepressant? ( Attiullah, N; Baymiller, S; Berlowitz, SL; Boland, RJ; Chelminski, I; Friedman, M; Posternak, MA; Rahman, S; Singer, S; Uy, KK; Zimmerman, M, 2005) |
| "The aim of the current study was to analyse the augmentation of minocycline with bupropion in treating depression." | 3.91 | The effect of bupropion augmentation of minocycline in the treatment of depression. ( Addepalli, V; Bendale, M; DSouza, SR; Kale, PP, 2019) |
| "In this global health case study, we describe a case of nicotine addiction due to chronic use of electronic cigarettes (e-cigarette) and discuss the beliefs on safety and awareness of their side effects." | 3.88 | Beliefs and reality of e-cigarette smoking. ( Inzamam Ali, M; Menakuru, S, 2018) |
| "To the best of our knowledge, this is the third published case of bupropion-related eosinophilia." | 3.79 | Eosinophilia associated with bupropion. ( Aguirre, C; Etxegarai, E; García, M; Lertxundi, U; Ruiz, B, 2013) |
| "Bupropion, which is widely used in patients with depressive disorder, may cause allergic reactions." | 3.79 | Delayed onset urticaria in depressive patients with bupropion prescription: a nationwide population-based study. ( Chang, YS; Chen, MH; Chen, PM; Chen, TJ; Chiang, HL; Hu, LY; Hu, TM; Hu, YW; Liu, CJ; Lu, T; Shen, CC; Su, TP; Su, VY; Teng, CJ; Tsai, CF; Wang, WS; Yeh, CM, 2013) |
| " Exposure to bupropion during pregnancy (OR = 3." | 3.76 | Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring. ( Figueroa, R, 2010) |
| "Bupropion is a trimethylated monocyclic phenylaminoketone that is an effective antidepressant in humans." | 3.75 | Bupropion hydrochloride. ( Becker, RE; Dufresne, RL; Weber, SS, 1984) |
| "Ninety-three patients with type 2 diabetes and major depressive disorder (MDD) received bupropion hydrochloride in a two-phase, open-label treatment trial." | 3.74 | Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion. ( Clouse, RE; Lustman, PJ; Nix, BD; Sayuk, GS; Williams, MM, 2007) |
| "To demonstrate that bupropion sustained release (SR) can reduce the symptoms of fatigue experienced by cancer patients." | 3.72 | Bupropion sustained release treatment reduces fatigue in cancer patients. ( Cullum, JL; Pelletier, G; Simpson, JS; Wojciechowski, AE, 2004) |
| "The authors report a case of bupropion-associated delirium characterized by disorganized thinking, memory impairment, fear, and agitation but not disorientation, delusions, hallucinations, or other perceptual distortions." | 3.68 | A case of bupropion-associated delirium. ( Dager, SR; Heritch, AJ, 1990) |
| "Patients (n = 20) with unipolar depression received baseline (medication-free) fluorine-18 deoxyglucose (FDG) positron emission tomography (PET) scan and then at least 6 weeks of bupropion or venlafaxine monotherapy in a single-blind crossover trial." | 2.71 | Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression. ( Benson, BE; Dunn, RT; Ketter, TA; Kimbrell, TA; Little, JT; Luckenbaugh, DA; Post, RM; Willis, MW, 2005) |
| "Bupropion treatment occupies less than 22% of DAT sites." | 2.70 | Bupropion occupancy of the dopamine transporter is low during clinical treatment. ( Christensen, BK; Goulding, VS; Houle, S; Hussey, D; Meyer, JH; Wilson, AA, 2002) |
| "Fluoxetine, however, was more frequently associated with sexual dysfunction compared with bupropion SR." | 2.70 | A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine. ( Ascher, J; Batey, S; Bolden-Watson, C; Book, MJ; Coleman, CC; Jamerson, B; King, BR; Metz, A; Richard, N; Segraves, RT, 2001) |
| " We sought to examine the efficacy and dosing patterns of bupropion in a naturalistic cohort of elderly subjects with major depression (MD)." | 2.70 | Bupropion SR in the naturalistic treatment of elderly patients with major depression. ( Doraiswamy, PM; McQuoid, DR; Steffens, DC, 2001) |
| "Bupropion SR was shown to be effective and well tolerated in decreasing the risk for relapse of depression for up to 44 weeks." | 2.70 | Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. ( Ascher, JA; Batey, SR; Bolden-Watson, C; Donahue, RM; Houser, TL; Metz, A; Weihs, KL, 2002) |
| "Bupropion has been previously shown to be particularly beneficial in bipolar and atypical depression." | 2.69 | Bupropion slow-release response in depression: diagnosis and biochemistry. ( Bowden, CL; DeVane, CL; Dominguez, RA; Goodnick, PJ, 1998) |
| "Bupropion-treated patients had small but statistically significant increases in supine diastolic blood pressure of 5." | 2.67 | The cardiovascular effects of bupropion and nortriptyline in depressed outpatients. ( Batey, SR; Holloman, LC; Johnston, JA; Kiev, A; Masco, HL; Wenger, TL, 1994) |
| "Bupropion treatment resulted in an improvement in depression on all outcome measures." | 2.67 | Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder. ( Apter, J; Ascher, J; Cunningham, L; Feighner, J; Ferguson, J; Ionescu-Pioggia, M; Johnston, JA; Merideth, C; Samara, B, 1994) |
| "Trazodone is an effective hypnotic for patients with antidepressant-associated insomnia." | 2.67 | Trazodone for antidepressant-associated insomnia. ( Adler, LA; Nierenberg, AA; Peselow, E; Rosenthal, M; Zornberg, G, 1994) |
| "Bupropion and trazodone were compared in a two-center, double-blind clinical trial of outpatients with moderate to severe major depression." | 2.67 | Comparison of bupropion and trazodone for the treatment of major depression. ( Billow, AA; Branconnier, RJ; Johnston, JA; Lineberry, CG; Samara, B; Weisler, RH, 1994) |
| "Bupropion was well tolerated; only four adverse events were reported at least 5% more often in the bupropion group than in the placebo group." | 2.67 | A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients. ( Boyer, WF; Carman, JS; Feighner, JP; Granacher, RP; Harto, NE; Johnston, JA; Lineberry, CG; Raymond, RN; Samara, B; Weisler, RH, 1990) |
| "Bupropion is a new antidepressant of the aminoketone class which is structurally unrelated to the tricyclics and which is relatively free of cardiac side effects in healthy depressed patients." | 2.66 | Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure. ( Bigger, JT; Giardina, EG; Glassman, AH; Johnson, LL; Roose, SP; Walsh, BT, 1987) |
| " Alternatively, a curvilinear dose-response relationship may exist for bupropion metabolites." | 2.66 | Bupropion in depression. II. The role of metabolites in clinical outcome. ( De Vane, CL; Golden, RN; Laizure, SC; Potter, WZ; Rudorfer, MV; Sherer, MA, 1988) |
| "A placebo-controlled double-blind study was conducted to test the antidepressant effects of bupropion at dosage levels of 300 or 450 mg/day." | 2.65 | Evaluation of the safety and efficacy of bupropion in depression. ( Halaris, AE; Reno, RM; Stern, WC; Van Wyck Fleet, J, 1983) |
| "Bupropion appears to be an effective broad-spectrum antidepressant with an excellent side effect profile." | 2.65 | Review of placebo-controlled trials with bupropion. ( Zung, WW, 1983) |
| "Bupropion is a novel, structurally unique (single ring) compound, radically different from tricyclic antidepressants in its pharmacologic profile." | 2.65 | Long-term efficacy and safety of bupropion. ( Othmer, E; Othmer, SC; Stern, WC; Van Wyck Fleet, J, 1983) |
| " Patients were then transferred to an ascending dosage regimen of bupropion." | 2.65 | Use of bupropion in patients who exhibit orthostatic hypotension on tricyclic antidepressants. ( Farid, FF; Singh, BN; Stern, WC; Tsai, SY; Wenger, TL, 1983) |
| "Bupropion was studied in four double-blind, placebo-controlled trials (N = 360) at dosages of 300-750 mg/day." | 2.65 | Methodologic approach to adverse events applied to bupropion clinical trials. ( Cato, AE; Cook, L; Heatherington, D; Starbuck, R, 1983) |
| "The incidence of a seizure was less than 1 per 1,000 at usual outpatient doses and less than 1 per 100 at usual inpatient doses." | 2.65 | Overview of clinically significant adverse reactions to bupropion. ( Cato, AE; Fleck, RJ; Harto-Truax, N; Manberg, PJ; Miller, LL; Sato, T; Stern, WC; Van Wyck Fleet, J, 1983) |
| "Bupropion and placebo were compared in hospitalized nonpsychotic depressed patients over a 28-day period." | 2.65 | The use of bupropion in hospitalized depressed patients. ( Feighner, JP; Merideth, CH, 1983) |
| "Bupropion was particularly efficacious in more severely ill and older patients." | 2.65 | A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients. ( Brodie, HK; Fabre, LF; Garver, D; Zung, WW, 1983) |
| " The side effect profile of each drug was clinically different from one another with a notable absence of anticholinergic side effects characteristic of the bupropion group." | 2.65 | A comparison of the safety and efficacy of bupropion HCL and amitriptyline hcl in depressed outpatients. ( Campos, PE; Miles, JE; Misri, S; Remick, RA; Van Wyck Fleet, J, 1982) |
| "Bupropion is an antidepressant thought to work through effects on norepinephrine and dopamine." | 2.44 | Bupropion extended-release for depressive disorders. ( Jefferson, JW, 2008) |
| "Insomnia and daytime sleepiness are often associated with depression." | 2.42 | Daytime sleepiness and insomnia as correlates of depression. ( Fava, M, 2004) |
| "Study data demonstrate that seizure incidence, which is a concern with high-dose IR, is substantially lower with the new SR formulation." | 2.40 | Bupropion sustained release: side effect profile. ( Settle, EC, 1998) |
| " The mechanism of action of antidepressants allows prediction of both adverse effects and therapeutic effects." | 2.40 | Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects. ( Stahl, SM, 1998) |
| " Pharmacokinetic and pharmacodynamic changes in this population may predispose patients to experience an increased number of adverse events." | 2.40 | Pharmacokinetic considerations of antidepressant use in the elderly. ( DeVane, CL; Pollock, BG, 1999) |
| "Nefazodone is a new antidepressant that combines blockade of the serotonin-2 receptor with serotonin uptake inhibition." | 2.39 | Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine. ( Preskorn, SH, 1995) |
| " There are substantial pharmacokinetic differences among the five major classes." | 2.38 | Pharmacokinetics of antidepressants: why and how they are relevant to treatment. ( Preskorn, SH, 1993) |
| "Severe orthostatic hypotension is more likely to develop in depressed patients with left ventricular impairment and/or in patients taking other drugs like diuretics or vasodilators." | 2.38 | Review of the cardiovascular effects of heterocyclic antidepressants. ( Glassman, AH; Preud'homme, XA, 1993) |
| "Major depressive disorder is a major health concern." | 2.38 | Somatic therapy for major depressive disorder: selection of an antidepressant. ( Burke, M; Preskorn, SH, 1992) |
| "The incidence of convulsions in patients receiving tricyclic antidepressants or bupropion was reviewed." | 2.36 | Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion. ( Peck, AW; Stern, WC; Watkinson, C, 1983) |
| "Bupropion is a selective norepinephrine and dopamine reuptakeinhibitor." | 1.51 | [Manic Shift Due to the Use of Bupropion in Bipolar Depression:Two Case Reports]. ( Görgülü, Y; Kahyacı Kılıç, E; Köse Çınar, R; Sönmez, MB, 2019) |
| "Bupropion is a dopamine and norepinephrine reuptake inhibitor approved for the treatment of depression and smoking cessation." | 1.40 | Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion. ( Brünen, S; Hiemke, C; Laib, AK; Pfeifer, P; Vincent, P, 2014) |
| "Bupropion is a relatively new and popular medication for depression, with seizures as its major side effect." | 1.40 | Charcoal hemoperfusion in bupropion overdose. ( Akdemir, HU; Calışkan, F; Duran, L; Güngörer, B; Katı, C; Ocak, M, 2014) |
| "Bupropion is a very popular medication prescribed to millions of patients globally for depression (Wellbutrin, GlaxoSmithKline, Research Triangle Park, NC) as well as an aid in smoking cessation (Zyban, GlaxoSmithKline, Research Triangle Park, NC)." | 1.36 | A case of bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation. ( Chon, SY; Riddel, C; Surovik, J, 2010) |
| "A reduction in dosing frequency is favored by Wellbutrin SR users and likely to improve their adherence to treatment." | 1.33 | An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey. ( Bennett, L; Edin, HM; Fehnel, SE; Granger, AL; Hogue, SL, 2006) |
| "Despite the superior side effect profile of the newer antidepressants over the tricyclics and monoamine oxidase inhibitors, all newer antidepressants are associated with a wide array of side effects." | 1.31 | The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists. ( Dording, CM; Fava, M; Gordon, J; Kornbluh, R; Mischoulon, D; Nierenberg, AA; Petersen, TJ; Rosenbaum, JE, 2002) |
| " Prospective studies utilizing flexible dosing of modern antidepressants and, if necessary, sequential trials of dissimilar medications are needed to confirm these findings." | 1.31 | Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants. ( Berman, SR; Fasiczka, AL; Frank, E; Friedman, ES; Nofzinger, EA; Reynolds, CF; Thase, ME, 2000) |
| "Bupropion SR treatment was associated with a reduction in measures of PLMD and an improvement in depression." | 1.31 | Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder. ( Berman, S; Fasiczka, A; Nofzinger, EA; Thase, ME, 2000) |
| "Bupropion SR as a treatment for depression also alleviates sexual dysfunction due to SSRI treatment." | 1.31 | Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction. ( Abouesh, AI; Clayton, AH; McGarvey, EL; Pinkerton, RC, 2001) |
| "With conservative dosing and close monitoring, combinations of SRIs with bupropion in this uncontrolled clinical series appeared to be safe and often more effective than monotherapy." | 1.30 | Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy. ( Baldessarini, RJ; Bodkin, JA; Gardner, DM; Lasser, RA; Wines, JD, 1997) |
| "Major depression and dysthymia are common and often disabling disorders in late life." | 1.30 | Diagnosis and treatment of depression in late life. ( Downs, NS; Zisook, S, 1998) |
| "Bupropion is an antidepressant with minimal sexual side effects." | 1.29 | Treatment of fluoxetine-induced sexual dysfunction with bupropion: a case report. ( Labbate, LA; Pollack, MH, 1994) |
| "Bupropion responders were more likely to have trough blood levels above 30 ng/ml (chi 2 = 3." | 1.28 | Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. ( Brickman, A; Goodnick, PJ; Klimas, NG; Sandoval, R, 1992) |
| "Bupropion hydrochloride is a phenylaminoketone antidepressant whose clinical pharmacology is poorly understood." | 1.28 | Organic mental disorders associated with bupropion in three patients. ( Ames, D; Szuba, MP; Wirshing, WC, 1992) |
| "The authors report two cases of menstrual irregularities associated with bupropion treatment." | 1.28 | Menstrual irregularities associated with bupropion treatment. ( Bakhai, Y; Halbreich, U; Rojansky, N; Wang, K, 1991) |
| "Tranylcypromine was effective in the treatment of 14 patients meeting both the National Institute of Mental Health and DSM-III-R criteria for winter depression." | 1.28 | Pharmacological responsiveness of winter depression. ( Del Medico, VJ; Dilsaver, SC; Jaeckle, S; Quadri, A, 1990) |
| " No clinically significant bupropion-related changes in blood pressure, pulse rates, respiration rate, body temperature, or laboratory parameters were recorded; only 41 patients were discontinued due to intolerance to adverse experiences." | 1.27 | Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients. ( Harto-Truax, N; Kirksey, DF, 1983) |
| "Bupropion was also found to be pharmacologically and biochemically distinct from tricyclics and monoamine oxidase inhibitors." | 1.27 | The pharmacologic basis for therapeutic interest in bupropion. ( Maxwell, RA; Soroko, FE, 1983) |
| "The SIADH was shown by rechallenge to be associated with imipramine, an antidepressant not previously associated with SIADH." | 1.27 | Imipramine-induced inappropriate ADH secretion. ( Jackson, W; Liskin, B; Roose, SP; Walsh, BT, 1984) |
| "Bupropion was associated with vivid dreaming and changes in attention, memory, and perception." | 1.26 | Perceptual changes with bupropion, a novel antidepressant. ( Becker, RE; Dufresne, RL, 1982) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 57 (20.88) | 18.7374 |
| 1990's | 98 (35.90) | 18.2507 |
| 2000's | 75 (27.47) | 29.6817 |
| 2010's | 41 (15.02) | 24.3611 |
| 2020's | 2 (0.73) | 2.80 |
| Authors | Studies |
|---|---|
| Kahyacı Kılıç, E | 1 |
| Görgülü, Y | 1 |
| Köse Çınar, R | 1 |
| Sönmez, MB | 1 |
| Stäuble, CK | 1 |
| Lampert, ML | 1 |
| Mikoteit, T | 1 |
| Hatzinger, M | 1 |
| Hersberger, KE | 1 |
| Meyer Zu Schwabedissen, HE | 1 |
| Allen, S | 2 |
| Thomas, J | 1 |
| Harrison, K | 1 |
| Emery, RL | 1 |
| Petersen, A | 1 |
| Winickoff, JP | 1 |
| Japuntich, S | 1 |
| Chu, CW | 1 |
| Chao, PC | 1 |
| Chang, HA | 1 |
| Liu, YW | 1 |
| Chang, TC | 1 |
| Lin, PY | 1 |
| Chang, CC | 1 |
| Goodwin, GM | 1 |
| Price, J | 1 |
| De Bodinat, C | 1 |
| Laredo, J | 1 |
| Xiang, XM | 1 |
| Phillips, DJ | 1 |
| Xing, S | 1 |
| Kim, S | 1 |
| Schumock, GT | 1 |
| Touchette, DR | 1 |
| Calip, GS | 1 |
| Leow, AD | 1 |
| Lee, TA | 1 |
| Ashrafi, F | 1 |
| Mousavi, S | 1 |
| Karimi, M | 1 |
| McCall, CA | 1 |
| Winkelman, JW | 1 |
| Menakuru, S | 1 |
| Inzamam Ali, M | 1 |
| Bendale, M | 1 |
| DSouza, SR | 1 |
| Addepalli, V | 1 |
| Kale, PP | 1 |
| Crespi, F | 1 |
| García, M | 1 |
| Ruiz, B | 1 |
| Aguirre, C | 1 |
| Etxegarai, E | 1 |
| Lertxundi, U | 1 |
| Hu, LY | 2 |
| Liu, CJ | 1 |
| Lu, T | 2 |
| Hu, TM | 1 |
| Tsai, CF | 1 |
| Hu, YW | 1 |
| Shen, CC | 1 |
| Chang, YS | 1 |
| Chen, MH | 1 |
| Teng, CJ | 1 |
| Chiang, HL | 1 |
| Yeh, CM | 1 |
| Su, VY | 1 |
| Wang, WS | 1 |
| Chen, PM | 1 |
| Chen, TJ | 1 |
| Su, TP | 1 |
| Laib, AK | 1 |
| Brünen, S | 1 |
| Pfeifer, P | 1 |
| Vincent, P | 1 |
| Hiemke, C | 1 |
| Akdemir, HU | 1 |
| Calışkan, F | 1 |
| Duran, L | 1 |
| Katı, C | 1 |
| Güngörer, B | 1 |
| Ocak, M | 1 |
| Bruder, GE | 1 |
| Alvarenga, JE | 1 |
| Alschuler, D | 1 |
| Abraham, K | 1 |
| Keilp, JG | 1 |
| Hellerstein, DJ | 1 |
| Stewart, JW | 3 |
| McGrath, PJ | 2 |
| Zvolensky, MJ | 1 |
| Farris, SG | 1 |
| Leventhal, AM | 1 |
| Ditre, JW | 1 |
| Schmidt, NB | 1 |
| Pytka, K | 1 |
| Rapacz, A | 1 |
| Zygmunt, M | 1 |
| Olczyk, A | 1 |
| Waszkielewicz, A | 1 |
| Sapa, J | 1 |
| Filipek, B | 1 |
| Evrensel, A | 1 |
| Ceylan, ME | 1 |
| Lai, CH | 1 |
| Singman, EL | 1 |
| Hocum, B | 1 |
| Yohannan, J | 1 |
| Pearson, V | 1 |
| Chen, S | 1 |
| Conwell, Y | 1 |
| He, J | 1 |
| Lu, N | 1 |
| Wu, J | 1 |
| Chen, YT | 1 |
| Bolen, RD | 1 |
| Campbell, Z | 1 |
| Bonilha, L | 1 |
| Edwards, JC | 1 |
| Li, QS | 1 |
| Tian, C | 1 |
| Seabrook, GR | 1 |
| Drevets, WC | 2 |
| Narayan, VA | 1 |
| Stasiuk, W | 1 |
| Szopa, A | 1 |
| Serefko, A | 1 |
| Wyska, E | 1 |
| Świąder, K | 1 |
| Dudka, J | 1 |
| Wlaź, P | 1 |
| Poleszak, E | 1 |
| Jha, MK | 1 |
| Minhajuddin, A | 1 |
| Gadad, BS | 1 |
| Greer, T | 1 |
| Grannemann, B | 1 |
| Soyombo, A | 1 |
| Mayes, TL | 1 |
| Rush, AJ | 4 |
| Trivedi, MH | 3 |
| Hussain, H | 1 |
| Butt, MA | 1 |
| Evins, AE | 1 |
| Culhane, MA | 1 |
| Alpert, JE | 1 |
| Pava, J | 1 |
| Liese, BS | 1 |
| Farabaugh, A | 1 |
| Fava, M | 8 |
| Davis, MF | 1 |
| Miller, HS | 1 |
| Nolan, PE | 1 |
| Deliyannides, RA | 1 |
| Quitkin, FM | 1 |
| Applebee, GA | 1 |
| Attarian, HP | 1 |
| Schenck, CH | 1 |
| Oulis, P | 1 |
| Kokras, N | 1 |
| Papadimitriou, GN | 1 |
| Masdrakis, VG | 1 |
| Schnoll, RA | 1 |
| Martinez, E | 1 |
| Tatum, KL | 1 |
| Weber, DM | 1 |
| Kuzla, N | 1 |
| Glass, M | 1 |
| Ridge, JA | 1 |
| Langer, C | 1 |
| Miyamoto, C | 1 |
| Wileyto, EP | 1 |
| Leone, F | 1 |
| Desmarais, JE | 1 |
| Looper, KJ | 1 |
| Figueroa, R | 1 |
| Surovik, J | 1 |
| Riddel, C | 1 |
| Chon, SY | 1 |
| Załuska, M | 1 |
| Dyduch, A | 1 |
| Bobo, WV | 1 |
| Chen, H | 1 |
| Nierenberg, AA | 5 |
| Kurian, BT | 1 |
| Warden, D | 1 |
| Morris, DW | 1 |
| Luther, JF | 1 |
| Husain, MM | 1 |
| Cook, IA | 1 |
| Lesser, IM | 1 |
| Kornstein, SG | 2 |
| Wisniewski, SR | 2 |
| Shelton, RC | 2 |
| Gaynes, BN | 1 |
| Farley, JF | 1 |
| Dusetzina, SB | 1 |
| Ellis, AR | 1 |
| Hansen, RA | 1 |
| Miller, WC | 1 |
| Stürmer, T | 1 |
| Friedman, ES | 2 |
| Davis, LL | 1 |
| Zisook, S | 4 |
| Calandra, C | 1 |
| Russo, RG | 1 |
| Luca, M | 1 |
| Lader, M | 1 |
| Takusagawa, HL | 1 |
| Hunter, RS | 1 |
| Jue, A | 1 |
| Pasquale, LR | 1 |
| Chen, TC | 1 |
| Song, HR | 1 |
| Jung, YE | 1 |
| Wang, HR | 1 |
| Woo, YS | 1 |
| Jun, TY | 1 |
| Bahk, WM | 1 |
| Saiz Ruiz, J | 1 |
| Gibert, J | 1 |
| Gutiérrez Fraile, M | 1 |
| Bobes, J | 1 |
| Vallejo, J | 1 |
| Iglesias, C | 1 |
| Iriarte, V | 1 |
| Hsiao, MC | 1 |
| Lin, KJ | 1 |
| Liu, CY | 1 |
| Schatz, DB | 1 |
| Shahani, L | 1 |
| McIntyre, RS | 1 |
| Mancini, DA | 1 |
| McCann, S | 1 |
| Srinivasan, J | 1 |
| Sagman, D | 1 |
| Kennedy, SH | 1 |
| Meyer, JH | 1 |
| Goulding, VS | 1 |
| Wilson, AA | 1 |
| Hussey, D | 1 |
| Christensen, BK | 1 |
| Houle, S | 1 |
| Joo, JH | 1 |
| Lenze, EJ | 1 |
| Mulsant, BH | 1 |
| Begley, AE | 1 |
| Weber, EM | 1 |
| Stack, JA | 1 |
| Mazumdar, S | 1 |
| Reynolds, CF | 4 |
| Pollock, BG | 3 |
| Ickowicz, A | 1 |
| Ott, GE | 1 |
| Rao, U | 1 |
| Nuccio, I | 1 |
| Lin, KM | 1 |
| Poland, RE | 1 |
| DeBattista, C | 1 |
| Solvason, HB | 1 |
| Poirier, J | 1 |
| Kendrick, E | 1 |
| Schatzberg, AF | 1 |
| Trivedi, M | 1 |
| Dording, CM | 1 |
| Mischoulon, D | 2 |
| Petersen, TJ | 1 |
| Kornbluh, R | 1 |
| Gordon, J | 1 |
| Rosenbaum, JE | 1 |
| Salomon, RM | 2 |
| Ripley, B | 1 |
| Kennedy, JS | 1 |
| Johnson, B | 1 |
| Schmidt, D | 1 |
| Zeitzer, JM | 1 |
| Nishino, S | 1 |
| Mignot, E | 1 |
| Labbate, LA | 3 |
| Croft, HA | 1 |
| Oleshansky, MA | 1 |
| Cotlar, MJ | 1 |
| Nemeroff, CB | 1 |
| Clayton, AH | 2 |
| Warnock, JK | 2 |
| Pinkerton, R | 1 |
| Sheldon-Keller, A | 1 |
| McGarvey, EL | 2 |
| Cullum, JL | 1 |
| Wojciechowski, AE | 1 |
| Pelletier, G | 1 |
| Simpson, JS | 1 |
| Dichter, GS | 1 |
| Tomarken, AJ | 1 |
| Sutton, SK | 1 |
| Bánki, MC | 1 |
| Chaudron, LH | 1 |
| Schoenecker, CJ | 1 |
| Lerman, C | 1 |
| Niaura, R | 1 |
| Collins, BN | 1 |
| Wileyto, P | 1 |
| Audrain-McGovern, J | 1 |
| Pinto, A | 1 |
| Hawk, L | 1 |
| Epstein, LH | 1 |
| Inoue, T | 1 |
| Kitaichi, T | 1 |
| Ogawa, T | 1 |
| Little, JT | 3 |
| Ketter, TA | 4 |
| Kimbrell, TA | 2 |
| Dunn, RT | 1 |
| Benson, BE | 1 |
| Willis, MW | 2 |
| Luckenbaugh, DA | 1 |
| Post, RM | 5 |
| Daviss, WB | 3 |
| Perel, JM | 2 |
| Rudolph, GR | 2 |
| Axelson, DA | 2 |
| Gilchrist, R | 2 |
| Nuss, S | 2 |
| Birmaher, B | 2 |
| Brent, DA | 2 |
| Zimmerman, M | 1 |
| Posternak, MA | 1 |
| Attiullah, N | 1 |
| Friedman, M | 1 |
| Boland, RJ | 1 |
| Baymiller, S | 1 |
| Berlowitz, SL | 1 |
| Rahman, S | 1 |
| Uy, KK | 1 |
| Singer, S | 1 |
| Chelminski, I | 1 |
| Taylor, MA | 1 |
| Vaidya, NA | 1 |
| Kast, RE | 2 |
| Altschuler, EL | 1 |
| Argyelán, M | 1 |
| Szabó, Z | 1 |
| Kanyó, B | 1 |
| Tanács, A | 1 |
| Kovács, Z | 1 |
| Janka, Z | 1 |
| Pávics, L | 1 |
| Menaster, MJ | 1 |
| Granger, AL | 1 |
| Fehnel, SE | 1 |
| Hogue, SL | 1 |
| Bennett, L | 1 |
| Edin, HM | 1 |
| Johnson, BW | 1 |
| Schmidt, DE | 1 |
| Vasudev, K | 1 |
| Macritchie, K | 1 |
| Geddes, J | 1 |
| Watson, S | 1 |
| Young, A | 1 |
| Miranda, J | 1 |
| Green, BL | 1 |
| Krupnick, JL | 1 |
| Chung, J | 1 |
| Siddique, J | 1 |
| Belin, T | 1 |
| Revicki, D | 1 |
| Csoka, AB | 1 |
| Shipko, S | 1 |
| Altshuler, LL | 1 |
| Leverich, GS | 1 |
| Frye, MA | 2 |
| Nolen, WA | 1 |
| Kupka, RW | 1 |
| Suppes, T | 1 |
| McElroy, S | 1 |
| Keck, PE | 1 |
| Denicoff, KD | 1 |
| Grunze, H | 1 |
| Walden, J | 1 |
| Kitchen, CM | 1 |
| Mintz, J | 1 |
| Foley, KF | 1 |
| DeSanty, KP | 1 |
| Taylor, MJ | 1 |
| Lustman, PJ | 1 |
| Williams, MM | 1 |
| Sayuk, GS | 1 |
| Nix, BD | 1 |
| Clouse, RE | 1 |
| Ait-Daoud, N | 1 |
| Lynch, WJ | 1 |
| Penberthy, JK | 1 |
| Breland, AB | 1 |
| Marzani-Nissen, GR | 1 |
| Johnson, BA | 1 |
| Jefferson, JW | 1 |
| Sokolski, KN | 1 |
| Kelwala, S | 1 |
| Stanley, M | 1 |
| Gershon, S | 1 |
| Feighner, JP | 7 |
| Halaris, AE | 3 |
| Stern, WC | 9 |
| Van Wyck Fleet, J | 5 |
| Reno, RM | 1 |
| Zung, WW | 2 |
| Davidson, J | 3 |
| Miller, R | 1 |
| Strickland, R | 1 |
| Manberg, P | 1 |
| Parrott, R | 1 |
| Mendels, J | 1 |
| Amin, MM | 1 |
| Chouinard, G | 2 |
| Cooper, AJ | 1 |
| Miles, JE | 2 |
| Remick, RA | 2 |
| Saxena, B | 1 |
| Secunda, SK | 1 |
| Singh, AN | 1 |
| Branconnier, RJ | 2 |
| Cole, JO | 4 |
| Ghazvinian, S | 1 |
| Spera, KF | 1 |
| Oxenkrug, GF | 1 |
| Bass, JL | 1 |
| Kane, JM | 1 |
| Cole, K | 1 |
| Sarantakos, S | 1 |
| Howard, A | 1 |
| Borenstein, M | 1 |
| Shopsin, B | 1 |
| Preskorn, SH | 10 |
| Kirksey, DF | 1 |
| Harto-Truax, N | 5 |
| Bauer, N | 1 |
| Othmer, E | 3 |
| Othmer, SC | 3 |
| Farid, FF | 1 |
| Wenger, TL | 4 |
| Tsai, SY | 1 |
| Singh, BN | 1 |
| Cohn, JB | 1 |
| Bustrack, J | 1 |
| Gardner, EA | 3 |
| Cato, AE | 2 |
| Cook, L | 1 |
| Starbuck, R | 1 |
| Heatherington, D | 1 |
| Manberg, PJ | 2 |
| Miller, LL | 2 |
| Sato, T | 1 |
| Fleck, RJ | 2 |
| Peck, AW | 1 |
| Watkinson, C | 1 |
| Cooper, BR | 1 |
| Howard, JL | 1 |
| Soroko, FE | 2 |
| Maxwell, RA | 1 |
| Merideth, CH | 1 |
| Fabre, LF | 1 |
| Brodie, HK | 1 |
| Garver, D | 1 |
| Pitts, WM | 1 |
| Fann, WE | 1 |
| Dressler, DM | 1 |
| Sajadi, C | 1 |
| Snyder, S | 1 |
| Ilaria, RL | 1 |
| Goode, DJ | 1 |
| Manning, AA | 1 |
| Clower, CG | 1 |
| Meredith, CH | 1 |
| Hendrickson, G | 2 |
| Carter, RG | 1 |
| Sheehan, DV | 1 |
| Liskin, B | 1 |
| Walsh, BT | 3 |
| Roose, SP | 5 |
| Jackson, W | 1 |
| Lai, CW | 1 |
| Dufresne, RL | 2 |
| Weber, SS | 1 |
| Becker, RE | 2 |
| Stern, W | 2 |
| Rogers, J | 1 |
| Miller, L | 2 |
| Katz, RJ | 1 |
| Sibel, M | 1 |
| Campos, PE | 1 |
| Misri, S | 1 |
| Paige, SR | 1 |
| Hendricks, SE | 1 |
| Fitzpatrick, DF | 1 |
| Balogh, S | 1 |
| Burke, WJ | 1 |
| Apter, JT | 1 |
| Kushner, SF | 1 |
| Woolfolk, RL | 1 |
| Ascher, JA | 8 |
| Colin, JN | 1 |
| Ferris, RM | 1 |
| Fibiger, HC | 1 |
| Golden, RN | 5 |
| Martin, P | 1 |
| Potter, WZ | 5 |
| Richelson, E | 1 |
| Levenson, JL | 1 |
| Kiev, A | 1 |
| Masco, HL | 1 |
| Johnston, JA | 10 |
| Batey, SR | 7 |
| Holloman, LC | 1 |
| Nofzinger, EA | 3 |
| Thase, ME | 4 |
| Frank, E | 2 |
| Jennings, JR | 1 |
| Fasiczka, AL | 2 |
| Sullivan, LR | 1 |
| Kupfer, DJ | 1 |
| Ferguson, J | 1 |
| Cunningham, L | 1 |
| Merideth, C | 1 |
| Apter, J | 1 |
| Feighner, J | 2 |
| Ionescu-Pioggia, M | 1 |
| Samara, B | 3 |
| Ascher, J | 2 |
| Pollack, MH | 2 |
| Glassman, AH | 4 |
| Adler, LA | 1 |
| Peselow, E | 1 |
| Zornberg, G | 1 |
| Rosenthal, M | 1 |
| Brown, ES | 1 |
| Dilsaver, SC | 2 |
| Shoaib, AM | 1 |
| Swann, AC | 1 |
| Weisler, RH | 2 |
| Lineberry, CG | 5 |
| Billow, AA | 2 |
| Kellner, CH | 2 |
| Pritchett, JT | 1 |
| Jackson, CW | 2 |
| Whitefield, SG | 1 |
| Akiskal, HS | 1 |
| Oslin, DW | 1 |
| Duffy, K | 1 |
| Walker, PW | 1 |
| Hughes, AR | 3 |
| Masand, P | 1 |
| Stern, TA | 1 |
| Workman, EA | 2 |
| Short, DD | 2 |
| Preud'homme, XA | 1 |
| Salzman, C | 3 |
| Hammerness, P | 1 |
| Gittelman, DK | 1 |
| Kirby, MG | 1 |
| Young, SJ | 1 |
| Lief, HI | 1 |
| Leonard, BE | 1 |
| Rothschild, AJ | 1 |
| Jenkins, JB | 1 |
| Schroeder, DH | 2 |
| Pazzaglia, PJ | 1 |
| Marangell, LB | 1 |
| George, MS | 2 |
| Callahan, AM | 1 |
| Hinton, ML | 1 |
| Chao, J | 1 |
| Marshall, RD | 1 |
| Liebowitz, MR | 1 |
| Stoudemire, A | 1 |
| Sweet, RA | 1 |
| Kirshner, M | 1 |
| Grimes, JB | 1 |
| Danielson, A | 1 |
| Benson, B | 1 |
| Mauskopf, JA | 1 |
| Simeon, GP | 1 |
| Miles, MA | 1 |
| Westlund, RE | 1 |
| Davidson, JR | 3 |
| Goodman, JF | 1 |
| Bodkin, JA | 1 |
| Lasser, RA | 1 |
| Wines, JD | 1 |
| Gardner, DM | 1 |
| Baldessarini, RJ | 1 |
| Edens, N | 1 |
| Newton, WP | 1 |
| Kavoussi, RJ | 1 |
| Segraves, RT | 3 |
| Connor, KM | 1 |
| Settle, EC | 3 |
| Downs, NS | 1 |
| Rye, DB | 1 |
| Dihenia, B | 1 |
| Bliwise, DL | 1 |
| Nelson, JC | 2 |
| Dunner, DL | 1 |
| Goodnick, PJ | 2 |
| Dominguez, RA | 1 |
| DeVane, CL | 2 |
| Bowden, CL | 1 |
| Efremova, I | 1 |
| Asnis, G | 1 |
| Stahl, SM | 1 |
| Swartz, CM | 1 |
| Guadagno, G | 1 |
| Mathé, AA | 1 |
| Luckenbaugh, D | 1 |
| Kirsch, MA | 1 |
| Louie, AK | 1 |
| Kent, RS | 1 |
| Hayford, KE | 1 |
| Patten, CA | 2 |
| Rummans, TA | 2 |
| Schroeder, DR | 1 |
| Offord, KP | 1 |
| Croghan, IT | 2 |
| Glover, ED | 1 |
| Sachs, DP | 1 |
| Hurt, RD | 2 |
| Horst, WD | 1 |
| Kales, HC | 1 |
| Mellow, AM | 1 |
| Fatemi, SH | 1 |
| Emamian, ES | 1 |
| Kist, DA | 1 |
| Halaris, A | 2 |
| Zhu, H | 2 |
| Feng, Y | 1 |
| Piletz, JE | 2 |
| Hirschfeld, RM | 1 |
| Hays, JT | 1 |
| Spatz, E | 1 |
| Howard, WT | 1 |
| Trappler, B | 1 |
| Miyashiro, AM | 1 |
| Kavoussi, R | 1 |
| Donahue, R | 2 |
| Weihs, KL | 2 |
| Houser, TL | 3 |
| Donahue, RM | 2 |
| Kizilbash, L | 1 |
| Rosenbaum, JF | 1 |
| Pierre, JM | 1 |
| Gitlin, MJ | 1 |
| Blass, DM | 1 |
| Pearson, VE | 1 |
| Berman, SR | 1 |
| Fasiczka, A | 1 |
| Berman, S | 1 |
| Zajecka, J | 1 |
| Ferguson, JM | 1 |
| Bentivoglio, P | 1 |
| Racusin, R | 1 |
| Brown, KM | 1 |
| Bostic, JQ | 1 |
| Wiley, L | 1 |
| Abouesh, AI | 1 |
| Pinkerton, RC | 1 |
| Shuchter, SR | 1 |
| Pedrelli, P | 1 |
| Sable, J | 1 |
| Deaciuc, SC | 1 |
| Pyne, JM | 1 |
| Bullock, D | 1 |
| Kaplan, RM | 1 |
| Smith, TL | 1 |
| Gillin, JC | 1 |
| Golshan, S | 1 |
| Kelsoe, JR | 1 |
| Williams, DK | 1 |
| Lara, DR | 1 |
| Busnello, ED | 1 |
| Souza, DO | 1 |
| Lineberry, TW | 1 |
| Peters, GE | 1 |
| Bostwick, JM | 1 |
| Walker, JB | 1 |
| Klein, RM | 1 |
| Yee, SL | 1 |
| Wagena, EJ | 1 |
| Huibers, MJ | 1 |
| van Schayck, CP | 1 |
| Enns, MW | 1 |
| Chengappa, KN | 1 |
| Kambhampati, RK | 1 |
| Perkins, K | 1 |
| Nigam, R | 1 |
| Anderson, T | 1 |
| Brar, JS | 1 |
| Vemulapalli, HK | 1 |
| Atzert, R | 1 |
| Key, P | 1 |
| Kang, JS | 1 |
| Levine, J | 2 |
| Coleman, CC | 1 |
| King, BR | 1 |
| Bolden-Watson, C | 3 |
| Book, MJ | 1 |
| Richard, N | 1 |
| Batey, S | 1 |
| Jamerson, B | 1 |
| Metz, A | 3 |
| Steffens, DC | 1 |
| Doraiswamy, PM | 1 |
| McQuoid, DR | 1 |
| Morton, K | 1 |
| Pradhan, SC | 1 |
| Nieuwstraten, CE | 1 |
| Dolovich, LR | 1 |
| Croft, H | 1 |
| Jamerson, BD | 1 |
| Leadbetter, R | 1 |
| Ali, J | 1 |
| Nasrallah, A | 1 |
| Lindsay De Vane, C | 1 |
| Villeneuve, A | 1 |
| Hollister, LE | 1 |
| Krajewski, K | 1 |
| Rustin, T | 1 |
| Gillespie, H | 1 |
| Sandoval, R | 1 |
| Brickman, A | 1 |
| Klimas, NG | 1 |
| Fichtner, CG | 1 |
| Braun, BG | 1 |
| Burke, M | 1 |
| Gelenberg, AJ | 1 |
| Ames, D | 1 |
| Wirshing, WC | 1 |
| Szuba, MP | 2 |
| Leuchter, AF | 1 |
| Head, LA | 1 |
| Khayrallah, MA | 2 |
| Stark, P | 1 |
| Lydiard, RB | 1 |
| Halbreich, U | 1 |
| Rojansky, N | 1 |
| Bakhai, Y | 1 |
| Wang, K | 1 |
| Dalack, GW | 1 |
| Woodring, S | 1 |
| Giardina, EG | 2 |
| Bittman, BJ | 1 |
| Young, RC | 1 |
| Schonlau, AY | 1 |
| Fernandez, F | 1 |
| Levy, JK | 1 |
| Raymond, RN | 1 |
| Harto, NE | 1 |
| Granacher, RP | 1 |
| Carman, JS | 1 |
| Boyer, WF | 1 |
| Dager, SR | 1 |
| Heritch, AJ | 1 |
| van Putten, T | 1 |
| Shaffer, I | 1 |
| Liberzon, I | 1 |
| Dequardo, JR | 1 |
| Silk, KR | 1 |
| Figiel, GS | 1 |
| Jarvis, MR | 1 |
| Del Medico, VJ | 1 |
| Quadri, A | 1 |
| Jaeckle, S | 1 |
| Michell, GF | 1 |
| Mebane, AH | 1 |
| Billings, CK | 1 |
| Ostrow, D | 1 |
| Pelton, S | 1 |
| Pope, HG | 1 |
| Hudson, JI | 1 |
| Katz, SE | 1 |
| Johnson, LL | 1 |
| Bigger, JT | 1 |
| Harsch, HH | 1 |
| Rudorfer, MV | 4 |
| Sherer, MA | 3 |
| Linnoila, M | 1 |
| De Vane, CL | 1 |
| Laizure, SC | 1 |
| Markey, SP | 1 |
| Risby, ED | 1 |
| Cowdry, RW | 1 |
| Mac, D | 1 |
| Rubin, AL | 1 |
| Charney, DS | 2 |
| Price, LH | 2 |
| Heninger, GR | 2 |
| Prien, RF | 1 |
| Blaine, JD | 1 |
| James, SP | 1 |
| Sack, DA | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Bupropion for the Prevention of Postpartum Smoking Relapse[NCT04098874] | Phase 4 | 200 participants (Anticipated) | Interventional | 2020-01-01 | Recruiting | ||
| Collaborative Care for Depressed Elders in China[NCT01287494] | Phase 4 | 320 participants (Anticipated) | Interventional | 2010-08-31 | Recruiting | ||
| Combining Medications to Enhance Depression Outcomes[NCT00590863] | Phase 4 | 665 participants (Actual) | Interventional | 2008-03-31 | Completed | ||
| A Pilot Double-Blind Randomized Placebo-Controlled Crossover Study to Investigate Rapid Antidepressant Effects of Leucine[NCT03079297] | Phase 2 | 16 participants (Actual) | Interventional | 2017-03-09 | Terminated (stopped due to Covid-19) | ||
| Combined Escitalopram/Bupropion as First Line Treatment for Depression, a Replication.[NCT00296712] | Phase 4 | 55 participants (Actual) | Interventional | 2005-02-28 | Completed | ||
| Sequenced Treatment Alternatives to Relieve Depression[NCT00021528] | Phase 4 | 4,000 participants | Interventional | 2001-07-31 | Completed | ||
| Applying Mindfulness-Based Cognitive Therapy to Treatment Resistant Depression[NCT00871299] | 173 participants (Actual) | Interventional | 2009-09-30 | Completed | |||
| The Role of Orexin in Human Panic Disorder[NCT02593682] | Phase 4 | 3 participants (Actual) | Interventional | 2016-05-31 | Completed | ||
| Music to Improve Sleep Quality in Adults With Depression and Insomnia: a Randomized Controlled Trial Using Mixed Methods[NCT03676491] | 112 participants (Actual) | Interventional | 2018-05-23 | Completed | |||
| Bio-behavioral Lung Cancer Prevention Program[NCT00322205] | Phase 4 | 555 participants | Interventional | 1999-06-30 | Completed | ||
| Phase II Randomized, Double-Blind Trial of Bupropion Versus Bupropion + Naltrexone for Smoking Cessation[NCT00419731] | Phase 2/Phase 3 | 120 participants (Anticipated) | Interventional | 2006-11-30 | Recruiting | ||
| Human Laboratory Study of Varenicline and Bupropion for Nicotine Dependence[NCT00749658] | Phase 2/Phase 3 | 121 participants (Actual) | Interventional | 2008-11-30 | Completed | ||
| [NCT00000526] | Phase 3 | 0 participants | Interventional | 1986-08-31 | Completed | ||
| Study of Antidepressants in Parkinson's Disease[NCT00086190] | Phase 3 | 115 participants (Actual) | Interventional | 2005-06-30 | Completed | ||
| Double-Blind, Placebo-Controlled, Randomized Trial of Adjunctive Lisdexamfetamine Dimesylate in Residual Symptoms of Major Depressive Disorder Partially Responsive to Selective Serotonin or Norepinephrine Reuptake Inhibitor Monotherapy[NCT01148979] | Phase 4 | 35 participants (Actual) | Interventional | 2010-09-30 | Completed | ||
| Motivational Interviewing to Reduce Substance Use Among Depression Patients[NCT02420561] | 307 participants (Actual) | Interventional | 2010-10-31 | Completed | |||
| Cortical rTMS as a Treatment for Depression[NCT05487911] | 50 participants (Anticipated) | Interventional | 2023-06-14 | Enrolling by invitation | |||
| Functional Connectivity Alterations in Suicidal Patients Among Opioid Users[NCT05489042] | 80 participants (Anticipated) | Interventional | 2022-01-04 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The Quality of Life Inventory (QOLI) is a 32-item comprehensive self-report of satisfaction in 16 areas of life, such as love, work, and health. Each area is rated in terms of satisfaction and the relationship of that area to overall quality of life. It yields an overall raw score and satisfaction ratings for the 16 individual areas of life. The QOLI raw score is an average of weighted satisfaction ratings computed only over areas of life judged to be Important or Extremely Important to the respondent. Higher scores indicate higher reported quality of life. (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | units on a scale (Mean) |
|---|---|
| Escitalopram + Bupropion SR | 0.6 |
| Venlafaxine XR + Mirtazapine | 0.4 |
| Escitalopram + Placebo | 0.4 |
Percentage of patients that achieve remission, as defined as QIDS total score below 6 for last 2 study visits. QIDS depression scores range from 0 (normal) to 27 (very severe). (NCT00590863)
Timeframe: Measured at Month 7
| Intervention | percentage of participants (Number) |
|---|---|
| Escitalopram + Bupropion SR | 46.6 |
| Venlafaxine XR + Mirtazapine | 41.8 |
| Escitalopram + Placebo | 46.0 |
"The Quick Inventory of Depressive Symptomatology, self-report (QIDS-SR), self-report is a 16-item measure of depression severity that includes the 9 criterion symptoms for MDD. Items are scored on a 4-point Likert scale, ranging from 0 to 3 (total score range, 0-27). Totals scores of ≤ 5 indicate no depression; 6-10 indicates mild depression; 11-15 indicates moderate depression; 16-20 indicates severe depression; and ≥ 21 indicates very severe depression. For purposes of this report, severe and very severe categories were combined as severe to very severe depression (≥ 16). The QIDS-A self-report has demonstrated acceptable psychometric properties." (NCT03079297)
Timeframe: Baseline to 14 days
| Intervention | score on a scale (Mean) |
|---|---|
| L-leucine | -6 |
| Maltodextrin | -8 |
"Response criteria defined based on QIDS-SR score at baseline and 14 days after treatment initiation.~The Quick Inventory of Depressive Symptomatology, self-report (QIDS-SR), self-report is a 16-item measure of depression severity that includes the 9 criterion symptoms for MDD. Items are scored on a 4-point Likert scale, ranging from 0 to 3 (total score range, 0-27). Totals scores of ≤ 5 indicate no depression; 6-10 indicates mild depression; 11-15 indicates moderate depression; 16-20 indicates severe depression; and ≥ 21 indicates very severe depression. For purposes of this report, severe and very severe categories were combined as severe to very severe depression (≥ 16). The QIDS-A self-report has demonstrated acceptable psychometric properties." (NCT03079297)
Timeframe: Baseline to 14 days
| Intervention | percentage of patients (Number) |
|---|---|
| L-leucine | 0 |
| Maltodextrin | 50 |
"Remission operationalized as QIDS-SR <=5.~The Quick Inventory of Depressive Symptomatology, self-report (QIDS-SR), self-report is a 16-item measure of depression severity that includes the 9 criterion symptoms for MDD. Items are scored on a 4-point Likert scale, ranging from 0 to 3 (total score range, 0-27). Totals scores of ≤ 5 indicate no depression; 6-10 indicates mild depression; 11-15 indicates moderate depression; 16-20 indicates severe depression; and ≥ 21 indicates very severe depression. For purposes of this report, severe and very severe categories were combined as severe to very severe depression (≥ 16). The QIDS-A self-report has demonstrated acceptable psychometric properties." (NCT03079297)
Timeframe: 14 days
| Intervention | percentage of patients (Number) |
|---|---|
| L-leucine | 0 |
| Maltodextrin | 25 |
"Anhedonia will be measured using Snaith-Hamilton Pleasure Scale (SHAPS).~The Snaith-Hamilton Pleasure Scale (SHAPS) is a 14-item scale that measures anhedonia, the inability to experience pleasure. The items cover the domains of: social interaction, food and drink, sensory experience, and interest/pastimes. A score of 2 or less constitutes a normal score, while an abnormal score is defined as 3 or more. Each item has four possible responses: strongly disagree, disagree, agree, or strongly agree. Either of the disagree responses score one point, and either of the agree responses score 0 points. Thus, the final score ranges from 0 to 14." (NCT03079297)
Timeframe: Baseline to 3 days, 7 days, and 14 days
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Anhedonia 3 days Change | Anhedonia 7 days Change | Anhedonia 14 days Change | |
| L-leucine | -0.21 | 0.79 | -0.07 |
| Maltodextrin | -0.46 | -1.46 | -2.21 |
"Fatigue will be measured with Multidimensional fatigue inventory~The Multidimensional Fatigue Inventory (MFI) is a 20-item self-report instrument designed to measure fatigue. It contains five scales: general fatigue (items 1, 5, 12, 16), mental fatigue (items 7, 11, 13, 19), physical fatigue (items 2, 8, 14, 20), reduced motivation (items 4, 9, 15, 18) and reduced activity (items 3, 6, 10, 17). Items are scored on a 5-point scale on which the participant expressed the degree to which the statement applied to him or her (from agreement yes, that is true to disagreement no, that is not true) in the previous days. Item scores are summed to create a sum score for each scale, ranging between 4 (best condition) and 20 (worst condition). Higher scores indicate more fatigue." (NCT03079297)
Timeframe: Baseline to 3 days, 7 days, and 14 days
| Intervention | units on a scale (Least Squares Mean) | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| General fatigue 3 days Change | General fatigue 7 days Change | General fatigue 14 days Change | Mental fatigue 3 days Change | Mental fatigue 7 days Change | Mental fatigue 14 days Change | Physical fatigue 3 days Change | Physical fatigue 7 days Change | Physical fatigue 14 days Change | Reduced motivation 3 days Change | Reduced motivation 7 days Change | Reduced motivation 14 days Change | Reduced activity 3 days Change | Reduced activity 7 days Change | Reduced activity 14 days Change | |
| L-leucine | -1.59 | -3.59 | -0.74 | -2.36 | -1.02 | -3.46 | -3.58 | 0.09 | -2.55 | -.032 | -0.71 | -5.51 | -2.80 | -4.14 | -4.47 |
| Maltodextrin | -0.70 | -3.20 | -3.70 | -0.71 | -4.71 | -3.96 | -0.55 | -1.80 | -3.80 | -0.26 | -1.26 | -2.76 | -0.47 | -3.97 | -8.14 |
"Psychosocial function will be measured using Work and Social Adjustment Scale~The Work and Social Adjustment Scale (WSAS) is a 5-item measure for impairment in functioning. Items are scored on an 8-point scale on how much participants' problems impaired their ability to carry out the activity (from Not at all to Very severely). Item scores are summed to create a sum score. The maximum score of the WSAS is 40, lower scores are better. A WSAS score above 20 appears to suggest moderately severe or worse psychopathology. Scores between 10 and 20 are associated with significant functional impairment but less severe clinical symptomatology. Scores below 10 appear to be associated with subclinical populations." (NCT03079297)
Timeframe: Baseline to 3 days, 7 days, and 14 days
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Psychosocial function 3 days Change | Psychosocial function7 days Change | Psychosocial function 14 days Change | |
| L-leucine | 1.49 | -1.18 | -9.38 |
| Maltodextrin | -2.57 | -7.57 | -7.32 |
"Adverse effect burden will be measured with Frequency Intensity and Burden of Side-effect rating scale (FIBSER).~The Frequency, Intensity, Burden of Side Effects Rating (FIBSER) scale was designed by Dr. Stephen Wisniewski for use in the U.S. STAR*D effectiveness study. It is a 3-item scale to assess side effects from antidepressant treatment. To use the FIBSER in measurement-based care, clinicians should consider item 3 (Burden). If the score is 0 to 2 (None to Mild interference with activities), no change in medication is needed. If the score is 3-4 (Moderate to Marked interference with activites), the side effects need to be addressed (i.e., change in dose, side effect antidote, etc). If the score is 5-6 (Severe interference with activities or Unable to Function), the dose needs to be decreased or the medication needs to be switched." (NCT03079297)
Timeframe: Baseline to 3 days, 7 days, and 14 days
| Intervention | units on a scale (Least Squares Mean) | ||
|---|---|---|---|
| Adverse effect burden 3 days Change | Adverse effect burden function 7 days Change | Adverse effect burden function 14 days Change | |
| L-leucine | 0 | 0 | 0 |
| Maltodextrin | 0 | 0 | -.25 |
Beck Depression Inventory II ranges from 0-63. Higher score indicates more severe depression. 0-13 minimal depression, 14-19 mild depression, 20-28 moderate depression, 29-63 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BDI-II score (Mean) |
|---|---|
| Paroxetine | -9.7 |
| Venlafaxine Extended Release | -9.6 |
| Placebo | -5.2 |
Brief Psychiatric Rating Scale. Maximum score 126. Higher score indicates greater psychiatric difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in BPRS score (Mean) |
|---|---|
| Paroxetine | -9.0 |
| Venlafaxine Extended Release | -9.8 |
| Placebo | -4.4 |
Geriatric Depression Scale ranges from 0-30. Higher score indicates more severe depression. 0-9 normal, 10-19 mild depression, 20-30 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in GDS score (Mean) |
|---|---|
| Paroxetine | -6.9 |
| Venlafaxine Extended Release | -6.9 |
| Placebo | -2.8 |
Change in Hamilton Rating Scale for Depression over 12 weeks. Hamilton Depression Rating Scale ranges from 0-50. Higher scores represent more significant depression. Mild depression ranges from 8-13, moderate depression from 14-18, severe 19-22 and very severe any score over 23. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in HAM-D score (Mean) |
|---|---|
| Paroxetine | -13.0 |
| Venlafaxine Extended Release | -11.0 |
| Placebo | -6.8 |
Montgomery-Asberg Depression Rating Scale ranges from 0-60. Higher score indicates more severe depression. 0-6 normal, 7-19 mild depression, 20-34 moderate depression, greater than 34 severe depression. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in MADRS score (Mean) |
|---|---|
| Paroxetine | -13.6 |
| Venlafaxine Extended Release | -10.9 |
| Placebo | -6.6 |
Parkinson's Disease Questionnaire (PDQ-39) - Emotional Well-Being maximum score 24, minimum score of 0.Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 Emotional score (Mean) |
|---|---|
| Paroxetine | -21.4 |
| Venlafaxine Extended Release | -20.7 |
| Placebo | -10.9 |
Parkinson's Disease Questionnaire (PDQ-39) Total. Range 0-100. Lower score indicates a better perceived health status. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PDQ-39 score (Mean) |
|---|---|
| Paroxetine | -8.0 |
| Venlafaxine Extended Release | -8.4 |
| Placebo | -5.3 |
Pittsburgh Sleep Quality Index scores range from 0-21, with higher scores indicating severe sleep difficulties. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in PQSI score (Mean) |
|---|---|
| Paroxetine | -2.1 |
| Venlafaxine Extended Release | -2.6 |
| Placebo | -1.1 |
Short Form 36 Health Survey. Range 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 mental score (Mean) |
|---|---|
| Paroxetine | 11.4 |
| Venlafaxine Extended Release | 9.5 |
| Placebo | 4.8 |
Short Form 36 Health Survey - Mental Health subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Mental Health score (Mean) |
|---|---|
| Paroxetine | 16.7 |
| Venlafaxine Extended Release | 17.4 |
| Placebo | 9.7 |
Short Form 36 Health Survey - Emotional subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 Role score (Mean) |
|---|---|
| Paroxetine | 39.5 |
| Venlafaxine Extended Release | 26.9 |
| Placebo | 12.7 |
Short Form 36 Health Survey - Vitality subscale ranges from 0-100. Higher score indicates a better perceived quality of life. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in SF-36 vitality score (Mean) |
|---|---|
| Paroxetine | 13.5 |
| Venlafaxine Extended Release | 9.1 |
| Placebo | 4.7 |
Snaith Clinical Anxiety Scale. Range 0-21. Higher scores indicate increased anxiety. Score greater than 8 indicates clinical anxiety. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in CAS score (Mean) |
|---|---|
| Paroxetine | -3.6 |
| Venlafaxine Extended Release | -3.2 |
| Placebo | -2.4 |
Unified Parkinson's Disease Rating Scale. Higher score indicates more severe Parkinson's disease symptoms. Total maximum = 176. Mental maximum = 52, Activities of Daily Living maximum = 52, Motor maximum = 72. Minimum = 0. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS score (Mean) |
|---|---|
| Paroxetine | -8.7 |
| Venlafaxine Extended Release | -7.0 |
| Placebo | -4.3 |
Unified Parkinson's Disease Rating Scale - Bulbar maximum score 24, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-Bulbar score (Mean) |
|---|---|
| Paroxetine | -1.4 |
| Venlafaxine Extended Release | -1.4 |
| Placebo | -0.5 |
Unified Parkinson's Disease Rating Scale - Motor has a maximum score of 72, minimum score of 0. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-motor score (Mean) |
|---|---|
| Paroxetine | -4.3 |
| Venlafaxine Extended Release | -2.0 |
| Placebo | -1.0 |
Unified Parkinson's Disease Rating Scale - Tremor subscale ranges from 0-23. Higher score indicates more severe Parkinson's disease symptoms. (NCT00086190)
Timeframe: from the beginning (0 weeks) to end (12 weeks) of the double-blind phase
| Intervention | Change in UPDRS-tremor score (Mean) |
|---|---|
| Paroxetine | 0.4 |
| Venlafaxine Extended Release | 0.5 |
| Placebo | -0.6 |
The Montgomery-Asberg Depression Rating Scale Dysphoric Apathy Retardation subfactor (MDAR) is a 5-item subscale of the clinician-administered 10-item Montgomery-Asberg Depression Rating Scale (MADRS). MDAR score can range from 0-30 with a higher score representing a greater severity of depressive symptoms. (NCT01148979)
Timeframe: Baseline to 4 weeks of treatment
| Intervention | scores on a scale (Mean) | ||
|---|---|---|---|
| Baseline Mean MDAR score | Week 4 Mean MDAR score | Change from BL in mean MDAR score | |
| Lisdexamfetamine Dimesylate (Vyvanse) | 13.46 | 6.36 | -7.08 |
| Placebo Adjunct | 12.57 | 9.08 | -3.49 |
53 reviews available for bupropion and Depression, Endogenous
| Article | Year |
|---|---|
Interactions between tamoxifen and antidepressants via cytochrome P450 2D6.
Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 In | 2009 |
Bupropion: efficacy and safety in the treatment of depression.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Drug Interactions; Humans | 2011 |
Antidepressant-related erectile dysfunction: management via avoidance, switching antidepressants, antidotes, and adaptation.
Topics: Antidepressive Agents; Bupropion; Controlled Clinical Trials as Topic; Depressive Disorder; Doxepin; | 2003 |
Improving antidepressant adherence.
Topics: Antidepressive Agents; Bupropion; Cyclohexanols; Delayed-Action Preparations; Depressive Disorder; H | 2003 |
[Antidepressive pharmacotherapy: changing paradigms].
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Dopamine; Dopamine Uptake | 2004 |
Daytime sleepiness and insomnia as correlates of depression.
Topics: Antidepressive Agents; Benzhydryl Compounds; Bupropion; Comorbidity; Depressive Disorder; Disorders | 2004 |
[Therapeutic strategy for drug resistant depression].
Topics: Animals; Antidepressive Agents; Biogenic Monoamines; Bupropion; Clomipramine; Depressive Disorder; D | 2004 |
Why isn't bupropion the most frequently prescribed antidepressant?
Topics: Adult; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; | 2005 |
Topiramate for acute affective episodes in bipolar disorder.
Topics: Affective Disorders, Psychotic; Antimanic Agents; Bipolar Disorder; Bupropion; Depressive Disorder; | 2006 |
Bupropion: pharmacology and therapeutic applications.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Depressive Disorder; | 2006 |
Strategies for managing antidepressant-induced sexual dysfunction: a review.
Topics: Antidepressive Agents; Bupropion; Buspirone; Depressive Disorder; Erectile Dysfunction; Female; Gink | 2006 |
Treating smoking dependence in depressed alcoholics.
Topics: Alcoholism; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cognitive Behavioral Therapy | 2006 |
Bupropion extended-release for depressive disorders.
Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Delayed-Action | 2008 |
History of antidepressants: successes and failures.
Topics: Albuterol; Animals; Antidepressive Agents; Brompheniramine; Bupropion; Clinical Trials as Topic; Dep | 1983 |
The new generation of antidepressants.
Topics: Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Brompheniramin | 1983 |
The cardiovascular profile of bupropion.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Blood Pressure; Bupropion; Cardiovascular Disease | 1983 |
Incidence of seizures during treatment with tricyclic antidepressant drugs and bupropion.
Topics: Antidepressive Agents; Bupropion; Depressive Disorder; Dose-Response Relationship, Drug; Humans; Imi | 1983 |
Bupropion hydrochloride.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain Chemistry; Bupropion; Clinical Trials as Top | 1984 |
Comparison of the tolerability of bupropion, fluoxetine, imipramine, nefazodone, paroxetine, sertraline, and venlafaxine.
Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Cyclohexanols; Depressi | 1995 |
Bupropion: a review of its mechanism of antidepressant activity.
Topics: Animals; Antidepressive Agents; Brain; Bupropion; Depressive Disorder; Dopamine; Down-Regulation; Hu | 1995 |
Bupropion: a review of its mechanism of antidepressant activity.
Topics: Animals; Antidepressive Agents; Brain; Bupropion; Depressive Disorder; Dopamine; Down-Regulation; Hu | 1995 |
Bupropion: a review of its mechanism of antidepressant activity.
Topics: Animals; Antidepressive Agents; Brain; Bupropion; Depressive Disorder; Dopamine; Down-Regulation; Hu | 1995 |
Bupropion: a review of its mechanism of antidepressant activity.
Topics: Animals; Antidepressive Agents; Brain; Bupropion; Depressive Disorder; Dopamine; Down-Regulation; Hu | 1995 |
Geriatric depression: brain imaging correlates and pharmacologic considerations.
Topics: Age Factors; Aged; Antidepressive Agents; Brain; Bupropion; Cerebrovascular Circulation; Cyclohexano | 1994 |
Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies.
Topics: Age Factors; Animals; Anti-Arrhythmia Agents; Antidepressive Agents; Antidepressive Agents, Tricycli | 1994 |
Dysthymic and cyclothymic depressions: therapeutic considerations.
Topics: Adolescent; Adult; Antidepressive Agents, Tricyclic; Bipolar Disorder; Bupropion; Child; Combined Mo | 1994 |
Bupropion and secondary mania. Is there a relationship?
Topics: Adult; Bipolar Disorder; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Humans; | 1993 |
Dose-effect and concentration-effect relationships with new antidepressants.
Topics: Antidepressive Agents; Bupropion; Depressive Disorder; Dopamine; Dose-Response Relationship, Drug; H | 1993 |
Pharmacokinetics of antidepressants: why and how they are relevant to treatment.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Biological Availability; Bupropion; Depress | 1993 |
Atypical antidepressants versus imipramine in the treatment of major depression: a meta-analysis.
Topics: Antidepressive Agents; Bupropion; Depressive Disorder; Fluoxetine; Humans; Imipramine; Trazodone | 1993 |
Review of the cardiovascular effects of heterocyclic antidepressants.
Topics: Amoxapine; Antidepressive Agents; Antidepressive Agents, Tricyclic; Arrhythmias, Cardiac; Bupropion; | 1993 |
Pharmacologic treatment of depression in the elderly.
Topics: Age Factors; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Depressive Di | 1993 |
New approaches to the treatment of depression.
Topics: Antidepressive Agents, Second-Generation; Brain; Bupropion; Citalopram; Cyclohexanols; Depressive Di | 1996 |
The diagnosis and treatment of late-life depression.
Topics: Age Factors; Aged; Antidepressive Agents; Anxiety Disorders; Bupropion; Cyclohexanols; Depressive Di | 1996 |
New antidepressant drugs and the treatment of depression in the medically ill patient.
Topics: Adjustment Disorders; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive | 1996 |
Bupropion sustained release: a therapeutic overview.
Topics: 1-Naphthylamine; Antidepressive Agents, Second-Generation; Bupropion; Clinical Trials as Topic; Dela | 1998 |
Depression, sleep, and antidepressants.
Topics: Adult; Antidepressive Agents; Bupropion; Circadian Rhythm; Comorbidity; Depressive Disorder; Electro | 1998 |
Bupropion sustained release: side effect profile.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Delayed-Actio | 1998 |
Augmentation strategies with serotonergic-noradrenergic combinations.
Topics: Adrenergic Uptake Inhibitors; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Cl | 1998 |
Treatment of antidepressant nonresponders: augmentation or switch?
Topics: Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Drug Administration | 1998 |
Selecting an antidepressant by using mechanism of action to enhance efficacy and avoid side effects.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Cyclohexanols; Depressive Disord | 1998 |
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder; Humans; Pip | 1998 |
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder; Humans; Pip | 1998 |
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder; Humans; Pip | 1998 |
Mechanisms of action and clinical characteristics of three atypical antidepressants: venlafaxine, nefazodone, bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Depressive Disorder; Humans; Pip | 1998 |
Care of the sexually active depressed patient.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Clinical Tria | 1999 |
Practical considerations for the treatment of depression in elderly and very elderly long-term care patients.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Ge | 1999 |
Treatment of depression in patients with heart disease.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Comorbidity; | 1999 |
Pharmacokinetic considerations of antidepressant use in the elderly.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antidepressive Agents; Antidepressive Agents, Second-Ge | 1999 |
Management of nonresponse and intolerance: switching strategies.
Topics: Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Depressive Disorder; Drug Admini | 2000 |
Strategies for the treatment of antidepressant-related sexual dysfunction.
Topics: Antidepressive Agents; Bupropion; Buspirone; Central Nervous System Stimulants; Depressive Disorder; | 2001 |
The effects of antidepressants on sexual functioning in depressed patients: a review.
Topics: Adult; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 2001 |
Bupropion versus selective serotonin-reuptake inhibitors for treatment of depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Double-Blind | 2001 |
Somatic therapy for major depressive disorder: selection of an antidepressant.
Topics: 1-Naphthylamine; Antidepressive Agents; Bupropion; Depressive Disorder; Humans; Nortriptyline; Sertr | 1992 |
Monoamine oxidase inhibitors and atypical antidepressants.
Topics: Aged; Antidepressive Agents; Bupropion; Depressive Disorder; Fluoxetine; Humans; Methylphenidate; Mo | 1992 |
Should bupropion dosage be adjusted based upon therapeutic drug monitoring?
Topics: Bupropion; Depressive Disorder; Drug Monitoring; Humans | 1991 |
Speed of onset of action of the newer antidepressants--fluoxetine and bupropion.
Topics: Antidepressive Agents; Bupropion; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Meta | 1991 |
Psychopharmacotherapy of psychiatric syndromes in asymptomatic and symptomatic HIV infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antidepressive Agents; Anxiety Disorders; Bupropion; Depr | 1991 |
Antidepressant drug therapy for bulimia: current status.
Topics: Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method | 1986 |
98 trials available for bupropion and Depression, Endogenous
| Article | Year |
|---|---|
Bupropion for postpartum smoking relapse: A remote protocol for a two-arm, double-blind, placebo-controlled randomized clinical trial.
Topics: Antidepressive Agents; Bupropion; COVID-19; Delayed-Action Preparations; Depressive Disorder; Depres | 2021 |
Neurocognitive predictors of antidepressant clinical response.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Case-Control Studies; Citalopram; Depres | 2014 |
Depression care management for adults older than 60 years in primary care clinics in urban China: a cluster-randomised trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Bupropion; China; Depressive Disorder; Health Policy | 2015 |
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Topics: Adult; Antidepressive Agents; Bupropion; C-Reactive Protein; Citalopram; Depressive Disorder; Drug T | 2017 |
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Topics: Adult; Antidepressive Agents; Bupropion; C-Reactive Protein; Citalopram; Depressive Disorder; Drug T | 2017 |
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Topics: Adult; Antidepressive Agents; Bupropion; C-Reactive Protein; Citalopram; Depressive Disorder; Drug T | 2017 |
Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial.
Topics: Adult; Antidepressive Agents; Bupropion; C-Reactive Protein; Citalopram; Depressive Disorder; Drug T | 2017 |
A controlled trial of bupropion added to nicotine patch and behavioral therapy for smoking cessation in adults with unipolar depressive disorders.
Topics: Administration, Cutaneous; Adult; Bupropion; Cognitive Behavioral Therapy; Combined Modality Therapy | 2008 |
Does dual antidepressant therapy as initial treatment hasten and increase remission from depression?
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder; Depress | 2009 |
A bupropion smoking cessation clinical trial for cancer patients.
Topics: Administration, Cutaneous; Antidepressive Agents, Second-Generation; Bupropion; Depression; Depressi | 2010 |
Randomized comparison of selective serotonin reuptake inhibitor (escitalopram) monotherapy and antidepressant combination pharmacotherapy for major depressive disorder with melancholic features: a CO-MED report.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; | 2011 |
Baseline depression severity as a predictor of single and combination antidepressant treatment outcome: results from the CO-MED trial.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Citalopram; Cyclohexanols; Depressive Dis | 2012 |
Bupropion versus sertraline in the treatment of depressive patients with binge eating disorder: retrospective cohort study.
Topics: Adult; Antidepressive Agents; Binge-Eating Disorder; Body Mass Index; Bupropion; Depressive Disorder | 2012 |
Topiramate versus bupropion SR when added to mood stabilizer therapy for the depressive phase of bipolar disorder: a preliminary single-blind study.
Topics: Acute Disease; Adult; Anticonvulsants; Antimanic Agents; Bipolar Disorder; Bupropion; Depressive Dis | 2002 |
Bupropion occupancy of the dopamine transporter is low during clinical treatment.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Bupropion; Cocaine; Depressive Disorder | 2002 |
Effect of bupropion-SR on REM sleep: relationship to antidepressant response.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Female; Humans; Mal | 2002 |
A prospective trial of bupropion SR augmentation of partial and non-responders to serotonergic antidepressants.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depressive | 2003 |
Diurnal variation of cerebrospinal fluid hypocretin-1 (Orexin-A) levels in control and depressed subjects.
Topics: Adult; Antidepressive Agents; Antidepressive Agents, Second-Generation; Bupropion; Carrier Proteins; | 2003 |
A placebo-controlled trial of bupropion SR as an antidote for selective serotonin reuptake inhibitor-induced sexual dysfunction.
Topics: Administration, Oral; Adult; Antidepressive Agents, Second-Generation; Arousal; Bupropion; Delayed-A | 2004 |
Early- and late-onset startle modulation in unipolar depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Arousal; Blinking; Bupropion; Depressive Diso | 2004 |
Effect of bupropion on depression symptoms in a smoking cessation clinical trial.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Combined Modality Therapy; Depressive Disorder; | 2004 |
Bupropion and venlafaxine responders differ in pretreatment regional cerebral metabolism in unipolar depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain Mapping; Bupropion; Case-Control Studies; Cer | 2005 |
Steady-state pharmacokinetics of bupropion SR in juvenile patients.
Topics: Adolescent; Age Factors; Antidepressive Agents, Second-Generation; Area Under Curve; Attention Defic | 2005 |
Central neurochemical ultradian variability in depression.
Topics: Adult; Antidepressive Agents; Bupropion; Depressive Disorder; Female; Homovanillic Acid; Humans; Hyd | 2006 |
One-year outcomes of a randomized clinical trial treating depression in low-income minority women.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cognitive Behavioral Therapy; Combined M | 2006 |
Acute antidepressant response and plasma levels of bupropion and metabolites in a pediatric-aged sample: an exploratory study.
Topics: Administration, Oral; Adolescent; Adult; Antidepressive Agents, Second-Generation; Area Under Curve; | 2006 |
Mood switch in bipolar depression: comparison of adjunctive venlafaxine, bupropion and sertraline.
Topics: Adjuvants, Pharmaceutic; Adult; Affect; Antidepressive Agents; Antidepressive Agents, Second-Generat | 2006 |
History of antidepressants: successes and failures.
Topics: Albuterol; Animals; Antidepressive Agents; Brompheniramine; Bupropion; Clinical Trials as Topic; Dep | 1983 |
The new generation of antidepressants.
Topics: Alprazolam; Antidepressive Agents; Antidepressive Agents, Tricyclic; Benzodiazepines; Brompheniramin | 1983 |
Evaluation of the safety and efficacy of bupropion in depression.
Topics: Adolescent; Adult; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; | 1983 |
Review of placebo-controlled trials with bupropion.
Topics: Adult; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 1983 |
A double-blind comparison of bupropion and amitriptyline in depressed inpatients.
Topics: Adult; Amitriptyline; Antidepressive Agents; Appetite; Body Weight; Bupropion; Clinical Trials as To | 1983 |
A comparative study of bupropion and amitriptyline in depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Amitriptyline; Antidepressive Agents; Bupropion; Clinical | 1983 |
Bupropion and amitriptyline in the treatment of depressed patients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Amitriptyline; Antidepressive Agents; Bupropion; Clinical | 1983 |
Clinical pharmacology of bupropion and imipramine in elderly depressives.
Topics: Age Factors; Aged; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; | 1983 |
Safety and efficacy of bupropion in elderly patients: preliminary observations.
Topics: Age Factors; Aged; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; | 1983 |
Bupropion: a new clinical profile in the psychobiology of depression.
Topics: Antidepressive Agents; Bipolar Disorder; Body Weight; Bupropion; Clinical Trials as Topic; Depressiv | 1983 |
Antidepressant response and plasma concentrations of bupropion.
Topics: Adolescent; Adult; Aged; Amitriptyline; Antidepressive Agents; Bupropion; Clinical Trials as Topic; | 1983 |
Efficacy of bupropion in tricyclic-resistant or intolerant patients.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Clinical | 1983 |
Long-term efficacy and safety of bupropion.
Topics: Adult; Aged; Ambulatory Care; Amitriptyline; Antidepressive Agents; Bupropion; Clinical Trials as To | 1983 |
Use of bupropion in patients who exhibit orthostatic hypotension on tricyclic antidepressants.
Topics: Adult; Aged; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Clinical Trials as | 1983 |
Comparison of the effects of bupropion and amitriptyline on cardiac conduction in depressed patients.
Topics: Amitriptyline; Antidepressive Agents; Bupropion; Depressive Disorder; Electrocardiography; Heart Con | 1983 |
The cardiovascular profile of bupropion.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Blood Pressure; Bupropion; Cardiovascular Disease | 1983 |
Methodologic approach to adverse events applied to bupropion clinical trials.
Topics: Akathisia, Drug-Induced; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Diso | 1983 |
Overview of clinically significant adverse reactions to bupropion.
Topics: Adult; Aged; Akathisia, Drug-Induced; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, | 1983 |
The use of bupropion in hospitalized depressed patients.
Topics: Adult; Aged; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double | 1983 |
A multicenter evaluation of bupropion versus placebo in hospitalized depressed patients.
Topics: Adolescent; Adult; Aged; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Diso | 1983 |
Bupropion in depression: a tri-center placebo-controlled study.
Topics: Adult; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind | 1983 |
Comparison of bupropion alone and with haloperidol in schizo-affective disorder, depressed type.
Topics: Adolescent; Adult; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Haloperidol; H | 1983 |
A double-blind study of bupropion and placebo in depression.
Topics: Adult; Aged; Antidepressive Agents; Body Weight; Bupropion; Clinical Trials as Topic; Depressive Dis | 1984 |
Tricyclic-induced electroencephalogram abnormalities and plasma drug concentrations.
Topics: Adult; Aged; Amitriptyline; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Depr | 1984 |
Bupropion hydrochloride.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain Chemistry; Bupropion; Clinical Trials as Top | 1984 |
Clinical efficacy of the new antidepressant bupropion (Wellbutrin) [proceedings].
Topics: Adult; Aged; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Female | 1981 |
Clinical profile of the novel antidepressant bupropion.
Topics: Animals; Antidepressive Agents; Antidepressive Agents, Tricyclic; Bupropion; Clinical Trials as Topi | 1982 |
A comparison of the safety and efficacy of bupropion HCL and amitriptyline hcl in depressed outpatients.
Topics: Adult; Amitriptyline; Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorde | 1982 |
Amplitude/intensity functions of auditory event-related potentials predict responsiveness to bupropion in major depressive disorder.
Topics: Adult; Bupropion; Depressive Disorder; Evoked Potentials, Auditory; Female; Follow-Up Studies; Human | 1995 |
The cardiovascular effects of bupropion and nortriptyline in depressed outpatients.
Topics: Adult; Aged; Blood Pressure; Bupropion; Cardiovascular System; Depressive Disorder; Dose-Response Re | 1994 |
REM sleep enhancement by bupropion in depressed men.
Topics: Adult; Age Factors; Bupropion; Cognitive Behavioral Therapy; Depressive Disorder; Fluoxetine; Humans | 1995 |
Bupropion in tricyclic antidepressant nonresponders with unipolar major depressive disorder.
Topics: Adult; Age Factors; Aged; Ambulatory Care; Antidepressive Agents, Tricyclic; Bupropion; Depressive D | 1994 |
Trazodone for antidepressant-associated insomnia.
Topics: Adult; Bupropion; Confidence Intervals; Depressive Disorder; Dose-Response Relationship, Drug; Doubl | 1994 |
Comparison of bupropion and trazodone for the treatment of major depression.
Topics: Adult; Bupropion; Depressive Disorder; Double-Blind Method; Drug Administration Schedule; Female; Hu | 1994 |
Carbamazepine but not valproate induces bupropion metabolism.
Topics: Adult; Antidepressive Agents; Biotransformation; Bipolar Disorder; Bupropion; Carbamazepine; Cytochr | 1995 |
Bupropion plasma levels and CYP2D6 phenotype.
Topics: Aged; Antidepressive Agents, Second-Generation; Bupropion; Cytochrome P-450 CYP2D6; Depressive Disor | 1996 |
Venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cerebrovascular Circulation; Cyclohexano | 1996 |
Functional status in depressed patients: the relationship to disease severity and disease resolution.
Topics: Adolescent; Adult; Bupropion; Delayed-Action Preparations; Depressive Disorder; Disability Evaluatio | 1996 |
Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.
Topics: 1-Naphthylamine; Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Bupropion; Delayed | 1997 |
A prospective safety surveillance study for bupropion sustained-release in the treatment of depression.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Aged; Antidepressive Agents, Second-Gene | 1998 |
Bupropion slow-release response in depression: diagnosis and biochemistry.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depressive | 1998 |
Melancholia with onset during treatment with SSRIs.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Anxiety Dis | 1998 |
Venlafaxine but not bupropion decreases cerebrospinal fluid 5-hydroxyindoleacetic acid in unipolar depression.
Topics: Adult; Analysis of Variance; Antidepressive Agents, Second-Generation; Brain; Bupropion; Cross-Over | 1999 |
Efficacy of bupropion for smoking cessation in smokers with a former history of major depression or alcoholism.
Topics: Adult; Alcoholism; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; | 1999 |
Development of depression during placebo-controlled trials of bupropion for smoking cessation: case reports.
Topics: Adult; Bupropion; Case-Control Studies; Depressive Disorder; Double-Blind Method; Female; Follow-Up | 1999 |
Evaluation of sexual functioning in depressed outpatients: a double-blind comparison of sustained-release bupropion and sertraline treatment.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Bupropion; Delay | 2000 |
Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
Topics: Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Bupropion; Comorbidity; Delayed-Act | 2000 |
Bupropion sustained release in adolescents with comorbid attention-deficit/hyperactivity disorder and depression.
Topics: Administration, Oral; Adolescent; Antidepressive Agents, Second-Generation; Attention Deficit Disord | 2001 |
Bupropion sustained release for bereavement: results of an open trial.
Topics: Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bereavement; Bupropion; Delayed-A | 2001 |
Health-related quality-of-life measure enhances acute treatment response prediction in depressed inpatients.
Topics: Adult; Age of Onset; Aged; Anticonvulsants; Antidepressive Agents; Bupropion; Comorbidity; Depressiv | 2001 |
Bupropion sustained release as a smoking cessation treatment in remitted depressed patients maintained on treatment with selective serotonin reuptake inhibitor antidepressants.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Bupropion; Comorbidity; Delayed-Action Prepar | 2001 |
A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depressive | 2001 |
Bupropion SR in the naturalistic treatment of elderly patients with major depression.
Topics: Administration, Oral; Aged; Antidepressive Agents, Second-Generation; Bupropion; Comorbidity; Delaye | 2001 |
Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; D | 2002 |
Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks.
Topics: Adolescent; Adult; Aged; Antidepressive Agents, Second-Generation; Body Mass Index; Bupropion; Delay | 2002 |
Down-regulation of platelet imidazoline-1-binding sites after bupropion treatment.
Topics: Antidepressive Agents, Second-Generation; Binding Sites; Blood Platelets; Bupropion; Clonidine; Depr | 2002 |
Drugs for cocaine dependence: not easy.
Topics: Adult; Bupropion; Cocaine; Depressive Disorder; Female; Hospitalization; Humans; Male; Patient Dropo | 1992 |
A 102-center prospective study of seizure in association with bupropion.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Bupropion; Depressive Disorder; Drug Administration Sche | 1991 |
Speed of onset of action of the newer antidepressants--fluoxetine and bupropion.
Topics: Antidepressive Agents; Bupropion; Depressive Disorder; Double-Blind Method; Fluoxetine; Humans; Meta | 1991 |
Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Body Weight; Bupropion; Depressive Disorder; Dose-Res | 1991 |
Bupropion dosing recommendations.
Topics: Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Drug Administration | 1990 |
A fixed-dose (300 mg) efficacy study of bupropion and placebo in depressed outpatients.
Topics: Adult; Ambulatory Care; Antidepressive Agents; Bupropion; Depressive Disorder; Dose-Response Relatio | 1990 |
Bupropion for depression.
Topics: Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Drug Interactions; | 1989 |
The new generation antidepressants: promising innovations or disappointments?
Topics: Alprazolam; Antidepressive Agents; Benzodiazepines; Bupropion; Citalopram; Clinical Trials as Topic; | 1985 |
Double-blind comparison of doxepin versus bupropion in outpatients with a major depressive disorder.
Topics: Adult; Aged; Antidepressive Agents; Body Weight; Bupropion; Clinical Trials as Topic; Depressive Dis | 1986 |
Forms of atypical depression and their response to antidepressant drugs.
Topics: Adult; Amitriptyline; Antidepressive Agents, Tricyclic; Anxiety Disorders; Bupropion; Clinical Trial | 1986 |
Antidepressant drug therapy for bulimia: current status.
Topics: Antidepressive Agents; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method | 1986 |
Cardiovascular effects of imipramine and bupropion in depressed patients with congestive heart failure.
Topics: Aged; Angiocardiography; Antidepressive Agents; Blood Pressure; Bupropion; Clinical Trials as Topic; | 1987 |
Bupropion in depression. I. Biochemical effects and clinical response.
Topics: Adult; Bupropion; Clinical Trials as Topic; Depressive Disorder; Dopamine; Double-Blind Method; Fema | 1988 |
Bupropion in depression. II. The role of metabolites in clinical outcome.
Topics: Adult; Aged; Bupropion; Clinical Trials as Topic; Depressive Disorder; Double-Blind Method; Female; | 1988 |
Antidepressants reduce whole-body norepinephrine turnover while enhancing 6-hydroxymelatonin output.
Topics: Adult; Animals; Antidepressive Agents; Bupropion; Depressive Disorder; Desipramine; Female; Humans; | 1988 |
Where are those new antidepressants we were promised?
Topics: Antidepressive Agents; Bupropion; Clinical Trials as Topic; Clomipramine; Depressive Disorder; Human | 1988 |
Differential effect of amitriptyline and bupropion on primary and secondary depression: a pilot study.
Topics: Adolescent; Adult; Amitriptyline; Antidepressive Agents; Anxiety Disorders; Bupropion; Clinical Tria | 1988 |
Efficacy of lithium-tranylcypromine treatment in refractory depression.
Topics: Adult; Aged; Anti-Anxiety Agents; Benzodiazepines; Bupropion; Clinical Trials as Topic; Depressive D | 1985 |
128 other studies available for bupropion and Depression, Endogenous
| Article | Year |
|---|---|
[Manic Shift Due to the Use of Bupropion in Bipolar Depression:Two Case Reports].
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bipolar Disorder; Bupropion; | 2019 |
Nonresponse to high-dose bupropion for depression in a patient carrying
Topics: Adult; Alleles; Antidepressive Agents, Second-Generation; Bupropion; Cytochrome P-450 CYP2B6; Cytoch | 2020 |
Escitalopram induced thrombocytopenia reversed after shifting to bupropion in a depressive patient.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Citalopram; Depressive Disorder; Humans; | 2017 |
Emotional blunting with antidepressant treatments: A survey among depressed patients.
Topics: Adult; Affective Symptoms; Antidepressive Agents; Bupropion; Case-Control Studies; Depressive Disord | 2017 |
Nonepileptic Myoclonus Following Bupropion Overdose.
Topics: Adolescent; Anticonvulsants; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorde | 2018 |
Risk of Diabetes Hospitalization or Diabetes Drug Intensification in Patients With Depression and Diabetes Using Second-Generation Antipsychotics Compared to Other Depression Therapies.
Topics: Adolescent; Adult; Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Antip | 2018 |
Potential Role of Bupropion Sustained Release for Cancer-Related Fatigue: a Double-Blind, Placebo-Controlled Study
Topics: Adult; Aged; Aged, 80 and over; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action | 2018 |
Respiratory-Related Leg Movements of Sleep Are Associated With Serotonergic Antidepressants But Not Bupropion.
Topics: Antidepressive Agents; Bupropion; Depressive Disorder; Female; Humans; Male; Middle Aged; Nocturnal | 2018 |
Beliefs and reality of e-cigarette smoking.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Chills; Depressive Disorder; Electronic | 2018 |
The effect of bupropion augmentation of minocycline in the treatment of depression.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Brain; Bupropion; Depression; Depressive Disorder; | 2019 |
In vivo oxymetric analysis of mild hypercapnia upon cerebral oxygen, temperature and blood flow: markers of mood as proposed by concomitant bupropion challenge and electrochemical analysis?
Topics: Animals; Biomarkers; Brain; Bupropion; Depressive Disorder; Disease Models, Animal; Dopamine; Electr | 2013 |
Eosinophilia associated with bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Cough; Depressive Disorder; Eosinophilia; Femal | 2013 |
Delayed onset urticaria in depressive patients with bupropion prescription: a nationwide population-based study.
Topics: Adult; Age of Onset; Antidepressive Agents, Second-Generation; Bupropion; Cohort Studies; Depressive | 2013 |
Serum concentrations of hydroxybupropion for dose optimization of depressed patients treated with bupropion.
Topics: Antidepressive Agents, Second-Generation; Area Under Curve; Bupropion; Chromatography, High Pressure | 2014 |
Charcoal hemoperfusion in bupropion overdose.
Topics: Antidepressive Agents, Second-Generation; Antidotes; Bupropion; Charcoal; Depressive Disorder; Drug | 2014 |
Emotional disorders and smoking: relations to quit attempts and cessation strategies among treatment-seeking smokers.
Topics: Adult; Anxiety Disorders; Benzazepines; Bupropion; Cross-Sectional Studies; Depressive Disorder; Dop | 2015 |
Antidepressant-like activity of a new piperazine derivative of xanthone in the forced swim test in mice: The involvement of serotonergic system.
Topics: Animals; Antidepressive Agents; Bupropion; Depressive Disorder; Fenclonine; Fluoxetine; Male; Mice; | 2015 |
Bupropion induced premature ejaculation.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Diagnosis, Differential; H | 2014 |
The bupropion-related subcortical changes in a depression patient.
Topics: Amygdala; Antidepressive Agents, Second-Generation; Brain; Bupropion; Caudate Nucleus; Depressive Di | 2015 |
Fluvoxamine-associated oscillopsia and a role for personalized medication dosing.
Topics: Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bupropion; Depressive Disorder; Dopa | 2015 |
Have we underestimated the possibility of bupropion sustained-release addiction?
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depressive | 2016 |
Alpha coma related to intentional bupropion overdose.
Topics: Antidepressive Agents, Second-Generation; Brain; Bupropion; Coma; Depressive Disorder; Drug Overdose | 2016 |
Analysis of 23andMe antidepressant efficacy survey data: implication of circadian rhythm and neuroplasticity in bupropion response.
Topics: Adult; Antidepressive Agents; Bupropion; Chromosomes, Human, Pair 4; Circadian Rhythm; Citalopram; D | 2016 |
Influence of the selective antagonist of the NR2B subunit of the NMDA receptor, traxoprodil, on the antidepressant-like activity of desipramine, paroxetine, milnacipran, and bupropion in mice.
Topics: Analysis of Variance; Animals; Antidepressive Agents; Brain; Bupropion; Chromatography, High Pressur | 2017 |
Bupropion-induced hypomania in a patient with unipolar depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Bipolar Disorder; Bupropion; Depressive Disorder; D | 2008 |
Prescribing during pregnancy. Prenatal drug exposure and an untreated psychiatric disorder both present risks.
Topics: Antidepressive Agents, Tricyclic; Antimanic Agents; Bupropion; Depressive Disorder; Dopamine Uptake | 2008 |
Bupropion levels in breast milk for 4 mother-infant pairs: more answers to lingering questions.
Topics: Adult; Antidepressive Agents, Second-Generation; Breast Feeding; Bupropion; Delayed-Action Preparati | 2009 |
An angry bed partner.
Topics: Anger; Antidepressive Agents, Second-Generation; Bupropion; Coronary Artery Disease; Depressive Diso | 2009 |
Bupropion-induced sleepwalking.
Topics: Adrenergic Uptake Inhibitors; Bupropion; Delayed-Action Preparations; Depressive Disorder; Dopamine | 2010 |
Use of antidepressants during pregnancy and risk of attention-deficit/hyperactivity disorder in the offspring.
Topics: Adult; Antidepressive Agents, Second-Generation; Attention Deficit Disorder with Hyperactivity; Bipo | 2010 |
A case of bupropion-induced Stevens-Johnson syndrome with acute psoriatic exacerbation.
Topics: Acute Disease; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Drug Erupti | 2010 |
Bupropion in the treatment of depression in Parkinson's disease.
Topics: Aged; Antidepressive Agents, Second-Generation; Brain; Bupropion; Depressive Disorder; Female; Human | 2011 |
Does the presence of accompanying symptom clusters differentiate the comparative effectiveness of second-line medication strategies for treating depression?
Topics: Adult; Bias; Bupropion; Buspirone; Cluster Analysis; Cyclohexanols; Depressive Disorder; Dopamine Up | 2011 |
Foreword. A comprehensive review of bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Humans | 2011 |
Bilateral uveal effusion and angle-closure glaucoma associated with bupropion use.
Topics: Adult; Bupropion; Depressive Disorder; Dopamine Uptake Inhibitors; Female; Glaucoma, Angle-Closure; | 2012 |
Platelet count alterations associated with escitalopram, venlafaxine and bupropion in depressive patients.
Topics: Adult; Antidepressive Agents, Second-Generation; Blood Platelets; Bupropion; Citalopram; Cyclohexano | 2012 |
The interaction between dopamine transporter function, gender differences, and possible laterality in depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Brain; Bupropion; Depressive Disorder; Dopamine Pla | 2013 |
Tramadol precipitating serotonin syndrome in a patient on antidepressants.
Topics: Analgesics, Opioid; Antidepressive Agents; Bupropion; Citalopram; Depressive Disorder; Drug Therapy, | 2012 |
Risk factors for falls during treatment of late-life depression.
Topics: Accidental Falls; Age Factors; Aged; Antidepressive Agents; Blood Pressure; Bupropion; Depressive Di | 2002 |
Bupropion-methylphenidate combination and grand mal seizures.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Bupropion; Depressive Disorder; Dose-Resp | 2002 |
Depression, IV: STAR*D treatment trial for depression.
Topics: Algorithms; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Ther | 2003 |
Depression, IV: STAR*D treatment trial for depression.
Topics: Algorithms; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Ther | 2003 |
Depression, IV: STAR*D treatment trial for depression.
Topics: Algorithms; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Ther | 2003 |
Depression, IV: STAR*D treatment trial for depression.
Topics: Algorithms; Ambulatory Care; Antidepressive Agents; Bupropion; Citalopram; Cognitive Behavioral Ther | 2003 |
The pharmacologic management of SSRI-induced side effects: a survey of psychiatrists.
Topics: Akathisia, Drug-Induced; Antidepressive Agents, Second-Generation; Bupropion; Critical Pathways; Dat | 2002 |
Attention deficit hyperactivity disorder (ADHD)--life insurance implications.
Topics: Actuarial Analysis; Adolescent; Adult; Antidepressive Agents, Second-Generation; Attention Deficit D | 2003 |
Bupropion sustained release treatment reduces fatigue in cancer patients.
Topics: Adjustment Disorders; Adult; Aged; Ambulatory Care; Antidepressive Agents, Second-Generation; Anxiet | 2004 |
Bupropion and breastfeeding: a case of a possible infant seizure.
Topics: Adult; Antidepressive Agents, Second-Generation; Breast Feeding; Bupropion; Depressive Disorder; Fem | 2004 |
Psychopathology in neuropsychiatry: DSM and beyond.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Data Collection; Depressive Disord | 2005 |
Bupropion and chronic aphthous ulceration.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Chronic Disease; Depressive Disorder; Hu | 2005 |
Dopamine transporter availability in medication free and in bupropion treated depression: a 99mTc-TRODAT-1 SPECT study.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Corpus Striatum; Depressive Disorder; Do | 2005 |
Weight gain, sexual dysfunction, and bupropion.
Topics: Ambulatory Care; Bupropion; Delayed-Action Preparations; Depressive Disorder; Drug Labeling; Humans; | 2005 |
An assessment of patient preference and adherence to treatment with Wellbutrin SR: a web-based survey.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Bupropion; Delayed-Action Preparations; Depre | 2006 |
Persistent sexual side effects after SSRI discontinuation.
Topics: Adult; Androgens; Anxiety; Bupropion; Cabergoline; Citalopram; Depressive Disorder; Dopamine Agonist | 2006 |
Factors influencing glycemic control in type 2 diabetes during acute- and maintenance-phase treatment of major depressive disorder with bupropion.
Topics: Absorptiometry, Photon; Adult; Age of Onset; Antidepressive Agents, Second-Generation; Blood Glucose | 2007 |
Adjunctive aripiprazole for bupropion-resistant major depression.
Topics: Adult; Aged; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Aripiprazole; Bupropion | 2008 |
Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients.
Topics: Adolescent; Adult; Aged; Ambulatory Care; Antidepressive Agents; Bupropion; Depressive Disorder; Dru | 1983 |
Long-term preventive care in depression: the use of bupropion in patients intolerant of other antidepressants.
Topics: Adult; Aged; Ambulatory Care; Antidepressive Agents; Antidepressive Agents, Tricyclic; Body Weight; | 1983 |
Animal models used in prediction of antidepressant effects in man.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Bupropion; Depressive Disorder; Drug Evaluation, P | 1983 |
The pharmacologic basis for therapeutic interest in bupropion.
Topics: Animals; Antidepressive Agents; Behavior, Animal; Blood Pressure; Brain Chemistry; Bupropion; Condit | 1983 |
Schizo-affective disorder: diagnostic criteria.
Topics: Bupropion; Depressive Disorder; Humans; Manuals as Topic; Propiophenones; Psychotic Disorders | 1984 |
Bupropion in the treatment of psychotic depression: two case reports.
Topics: Adult; Antidepressive Agents; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Hal | 1984 |
Delineation of anxiety and phobic disorders responsive to monoamine oxidase inhibitors: implications for classification.
Topics: Alprazolam; Anxiety Disorders; Benzodiazepines; Bupropion; Depressive Disorder; Dexamethasone; Fear; | 1984 |
Imipramine-induced inappropriate ADH secretion.
Topics: Aged; Antidepressive Agents; Bupropion; Depressive Disorder; Female; Humans; Hyponatremia; Imipramin | 1984 |
Animal model of depression: tests of three structurally and pharmacologically novel antidepressant compounds.
Topics: Animals; Antidepressive Agents; Bupropion; Corticosterone; Depressive Disorder; Disease Models, Anim | 1982 |
Perceptual changes with bupropion, a novel antidepressant.
Topics: Antidepressive Agents; Attention; Bupropion; Depressive Disorder; Dreams; Humans; Memory; Perception | 1982 |
Bupropion/nortriptyline combination for refractory depression.
Topics: Bupropion; Depressive Disorder; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug | 1994 |
Priapism associated with bupropion treatment.
Topics: Bupropion; Clitoris; Depressive Disorder; Female; Humans; Male; Middle Aged; Priapism; Sex Factors | 1995 |
Treatment of fluoxetine-induced sexual dysfunction with bupropion: a case report.
Topics: Bupropion; Depressive Disorder; Drug Therapy, Combination; Erectile Dysfunction; Fluoxetine; Humans; | 1994 |
Depressive mania: response of residual depression to bupropion.
Topics: Adult; Bipolar Disorder; Bupropion; Depressive Disorder; Drug Therapy, Combination; Female; Humans; | 1994 |
Bupropion coadministration with electroconvulsive therapy: two case reports.
Topics: Adult; Bipolar Disorder; Bupropion; Combined Modality Therapy; Depressive Disorder; Electroconvulsiv | 1994 |
A systematic approach to the classification and pharmacotherapy of nonpsychotic major depression and dysthymia.
Topics: Antidepressive Agents, Tricyclic; Bupropion; Depressive Disorder; Humans; Selective Serotonin Reupta | 1994 |
The rise of serum aminotransferases in a patient treated with bupropion.
Topics: Aged; Alanine Transaminase; Aspartate Aminotransferases; Bipolar Disorder; Bupropion; Chemical and D | 1993 |
Improvement in fluoxetine-associated sexual dysfunction in patients switched to bupropion.
Topics: Ambulatory Care; Bupropion; Depressive Disorder; Female; Fluoxetine; Humans; Libido; Male; Middle Ag | 1993 |
Adjunctive yohimbine for treatment in refractory depression.
Topics: Bupropion; Depressive Disorder; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; | 1993 |
A seizure following bupropion overdose.
Topics: Adult; Bupropion; Depressive Disorder; Drug Overdose; Female; Humans; Seizures | 1993 |
Panic associated with combining fluoxetine and bupropion.
Topics: Adult; Bupropion; Depressive Disorder; Dopamine Uptake Inhibitors; Drug Administration Schedule; Dru | 1996 |
Bupropion treatment of depression to assist smoking cessation.
Topics: Bupropion; Comorbidity; Depressive Disorder; Female; Humans; Smoking; Smoking Cessation; Smoking Pre | 1996 |
Paroxetine/bupropion combination treatment for refractory depression.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Drug Resistance; Drug Ther | 1996 |
Spontaneous orgasm with the combined use of bupropion and sertraline.
Topics: 1-Naphthylamine; Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Dr | 1996 |
Treatment of headache with bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Humans; Male; Vascular Hea | 1997 |
Combining serotonin reuptake inhibitors and bupropion in partial responders to antidepressant monotherapy.
Topics: 1-Naphthylamine; Adult; Aged; Ambulatory Care; Anxiety Disorders; Bupropion; Depressive Disorder; Dr | 1997 |
SSRIs, bupropion, and sexual function.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Coitus; Depressive Disorder; Humans; Rep | 1997 |
Diagnosis and treatment of depression in late life.
Topics: Adult; Age Factors; Aged; Antidepressive Agents; Bupropion; Cognition Disorders; Combined Modality T | 1998 |
Reversal of atypical depression, sleepiness, and REM-sleep propensity in narcolepsy with bupropion.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Dopamine; Female; Humans; | 1998 |
Antidepressants in depressed patients with irritable bowel syndrome.
Topics: Acute Disease; Adult; Antidepressive Agents, Second-Generation; Bupropion; Colonic Diseases, Functio | 1998 |
Combination treatment with venlafaxine and bupropion.
Topics: Adult; Bupropion; Cyclohexanols; Depressive Disorder; Dopamine Uptake Inhibitors; Drug Administratio | 1999 |
Bupropion clarification.
Topics: Antidepressive Agents, Second-Generation; Bupropion; Comorbidity; Contraindications; Depressive Diso | 1999 |
Ileus as a possible result of bupropion in an elderly woman.
Topics: Age Factors; Aged; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Drug Th | 1999 |
Venlafaxine and bupropion combination therapy in a case of treatment-resistant depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Chronic Disease; Cyclohexanols; Depressi | 1999 |
Plasma agmatine and platelet imidazoline receptors in depression.
Topics: Agmatine; Antidepressive Agents, Second-Generation; Blood Platelets; Bupropion; Cohort Studies; Depr | 1999 |
Bupropion-induced psychosis.
Topics: Age Factors; Aged; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Drug Ad | 1999 |
Bupropion-amantadine-associated neurotoxicity.
Topics: Aged; Aged, 80 and over; Amantadine; Bupropion; Comorbidity; Confusion; Depressive Disorder; Drug In | 2000 |
Strategies for managing depression refractory to selective serotonin reuptake inhibitor treatment: a survey of clinicians.
Topics: Antimanic Agents; Bupropion; Depressive Disorder; Female; Humans; Lithium; Male; Professional Compet | 2000 |
Bupropion-tranylcypromine combination for treatment-refractory depression.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Depressive Disorder; Drug Therapy, Combi | 2000 |
SIADH with multiple antidepressants in a geriatric patient.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Bupropion; Cyclohexanols; Depressive Disorder; Hu | 2000 |
Treatment of men with major depression: a comparison of sequential cohorts treated with either cognitive-behavioral therapy or newer generation antidepressants.
Topics: Adult; Antidepressive Agents; Bupropion; Cognitive Behavioral Therapy; Depressive Disorder; Fluoxeti | 2000 |
Bupropion SR reduces periodic limb movements associated with arousals from sleep in depressed patients with periodic limb movement disorder.
Topics: Adult; Antidepressive Agents; Bupropion; Case-Control Studies; Delayed-Action Preparations; Depressi | 2000 |
Substitution of an SSRI with bupropion sustained release following SSRI-induced sexual dysfunction.
Topics: Adult; Antidepressive Agents, Second-Generation; Bupropion; Cyclohexanols; Delayed-Action Preparatio | 2001 |
Ondansetron rather than metoclopramide for bupropion-induced nausea.
Topics: Adult; Antiemetics; Bupropion; Depressive Disorder; Drug Interactions; Female; Humans; Metoclopramid | 2001 |
Bupropion-induced erythema multiforme.
Topics: Administration, Oral; Adult; Aftercare; Anti-Inflammatory Agents; Antidepressive Agents, Second-Gene | 2001 |
Type II error and antidepressants.
Topics: Age Factors; Aged; Antidepressive Agents; Bupropion; Delayed-Action Preparations; Depressive Disorde | 2001 |
Antidepressants in the treatment of patients with COPD: possible associations between smoking cigarettes, COPD and depression.
Topics: Antidepressive Agents; Bupropion; Depressive Disorder; Humans; Lung Diseases, Obstructive; Nortripty | 2001 |
Seizure during combination of trimipramine and bupropion.
Topics: Antidepressive Agents, Second-Generation; Antidepressive Agents, Tricyclic; Bupropion; Depressive Di | 2001 |
Smoking cessation and major depression.
Topics: Bupropion; Depressive Disorder; Dopamine Uptake Inhibitors; Humans; Smoking Cessation | 2001 |
[Duration of antidepressive treatments].
Topics: Antidepressive Agents, Tricyclic; Bupropion; Carbamazepine; Depressive Disorder; Dose-Response Relat | 1992 |
Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome.
Topics: Adult; Bupropion; Depressive Disorder; Fatigue Syndrome, Chronic; Female; Fluoxetine; Follow-Up Stud | 1992 |
Bupropion-associated mania in a patient with HIV infection.
Topics: Bipolar Disorder; Bupropion; Depressive Disorder; HIV Seropositivity; Humans; Male; Middle Aged | 1992 |
Bupropion-induced carbohydrate craving and weight gain.
Topics: Adult; Bupropion; Depressive Disorder; Dietary Carbohydrates; Feeding and Eating Disorders; Humans; | 1992 |
Imperfect drugs in an imperfect world.
Topics: Bulimia; Bupropion; Clinical Trials as Topic; Clozapine; Depressive Disorder; Humans; Nomifensine; P | 1992 |
Organic mental disorders associated with bupropion in three patients.
Topics: Adult; Antidepressive Agents; Auditory Perceptual Disorders; Bipolar Disorder; Bupropion; Depressive | 1992 |
Falling backward in two elderly patients taking bupropion.
Topics: Age Factors; Aged; Basal Ganglia Diseases; Bupropion; Depressive Disorder; Dyskinesia, Drug-Induced; | 1992 |
Catatonia associated with bupropion treatment.
Topics: Adult; Bupropion; Catatonia; Depressive Disorder; Humans; Male; Psychoses, Substance-Induced | 1992 |
Menstrual irregularities associated with bupropion treatment.
Topics: Adult; Antidepressive Agents; Bupropion; Depressive Disorder; Female; Humans; Menstruation Disturban | 1991 |
Cardiovascular effects of bupropion in depressed patients with heart disease.
Topics: Aged; Aged, 80 and over; Antidepressive Agents; Blood Pressure; Bupropion; Cardiovascular System; De | 1991 |
Mania in an elderly man treated with bupropion.
Topics: Aged; Antidepressive Agents; Bipolar Disorder; Bupropion; Depressive Disorder; Humans; Male; Propiop | 1991 |
Medication truths.
Topics: Aged; Antidepressive Agents; Bupropion; Depressive Disorder; Humans; Propiophenones | 1991 |
Tinnitus related to bupropion treatment.
Topics: Antidepressive Agents; Bupropion; Depressive Disorder; Drug Administration Schedule; Female; Fluoxet | 1991 |
Treatment choice after one antidepressant fails: a survey of northeastern psychiatrists.
Topics: Antidepressive Agents; Attitude of Health Personnel; Bupropion; Decision Making; Depressive Disorder | 1991 |
A case of bupropion-associated delirium.
Topics: Antidepressive Agents; Bupropion; Delirium; Depressive Disorder; Dose-Response Relationship, Drug; H | 1990 |
Delirium associated with bupropion.
Topics: Adult; Antidepressive Agents; Bupropion; Delirium; Depressive Disorder; Dose-Response Relationship, | 1990 |
Bupropion and delirium.
Topics: Aged; Amantadine; Antidepressive Agents; Bupropion; Delirium; Depressive Disorder; Drug Therapy, Com | 1990 |
Therapeutic drug monitoring of bupropion.
Topics: Antidepressive Agents; Bupropion; Depressive Disorder; Humans; Propiophenones | 1990 |
Electroconvulsive therapy in a depressed patient receiving bupropion.
Topics: Antidepressive Agents; Bupropion; Combined Modality Therapy; Depressive Disorder; Electroconvulsive | 1990 |
Pharmacological responsiveness of winter depression.
Topics: Adult; Antidepressive Agents; Bupropion; Depressive Disorder; Desipramine; Disorders of Excessive So | 1990 |
Effect of bupropion on chocolate craving.
Topics: Antidepressive Agents; Bupropion; Cacao; Depressive Disorder; Feeding Behavior; Female; Humans; Male | 1989 |
Bupropion treatment of refractory depression.
Topics: Antidepressive Agents; Bupropion; Depressive Disorder; Female; Humans; Middle Aged; Propiophenones | 1987 |
The effect of bupropion on prolactin in a patient with a pituitary microadenoma.
Topics: Adenoma; Antidepressive Agents; Bupropion; Depressive Disorder; Female; Humans; Middle Aged; Pituita | 1987 |
Rapid improvement of delusional depression following drug-induced seizures: case report.
Topics: Adult; Bupropion; Delusions; Depressive Disorder; Drug Therapy, Combination; Epilepsy, Tonic-Clonic; | 1985 |
Antidepressant drug therapy: the role of the new antidepressants.
Topics: Amoxapine; Antidepressive Agents; Bupropion; Cardiovascular Diseases; Depressive Disorder; Drug Eval | 1985 |
Psychoses associated with bupropion treatment.
Topics: Acute Disease; Adult; Aged; Antidepressive Agents; Bupropion; Depressive Disorder; Dopamine; Female; | 1985 |